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ABSTRACT 
Beclin 1 is a haplo-insufficient tumor suppressor that is decreased in many 
human tumors. The function of Beclin 1 in cancer has been attributed primarily to 
its role in the degradative process of autophagy. However, the role of autophagy 
itself in tumorigenesis is context-dependent and can be both preventive and 
promoting. Due to its dual function in cancer a better understanding of this 
process is necessary to develop potential novel cancer therapies. To gain insight 
into the role of autophagy in breast carcinoma, I analyzed the autophagy-
dependency of different subtypes of breast cancer. My results implicate that 
triple-negative breast carcinoma cells are more dependent on autophagy than 
luminal breast carcinoma cells. Chemical inhibition of autophagy decreased the 
tumorigenicity of triple-negative breast carcinoma cells with regard to proliferation 
and anchorage-independent growth. However, RNAi-mediated suppression of 
two autophagy genes, ATG5 and Beclin 1, revealed different outcomes. While 
suppression of ATG5 decreased glycolysis, Beclin 1 depletion did not affect the 
glycolytic rates. These results suggest autophagy-independent pro-tumorigenic 
effects of loss of Beclin 1 in cancer. 
Beclin 1 is a core component of the Vps34/Class III PI3K (PI3KC3) and 
Vps15/p150 complex that regulates multiple membrane trafficking events. I 
describe a novel mechanism of action for Beclin 1 in breast cancer involving its 
control of growth factor receptor signaling. I identify a specific stage of early 
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endosome maturation that is regulated by Beclin 1, the transition of APPL1-
containing phosphatidyIinositol 3-phosphate-negative (PI3P-) endosomes to 
PI3P+ endosomes. Beclin 1 regulates PI3P production in response to growth 
factor stimulation to control the residency time of growth factor receptors in the 
PI3P-/APPL+ signaling competent compartment. As a result, suppression of 
BECN1 sustains growth factor stimulated AKT and ERK activation resulting in 
increased breast carcinoma cell invasion. In human breast tumors, Beclin 1 
expression is inversely correlated with AKT and ERK phosphorylation. Taken 
together my data identify a novel role for Beclin 1 in regulating growth factor 
signaling and reveal a mechanism by which loss of Beclin 1 expression would 
enhance breast cancer progression independent of its impact on autophagy.
viii
TABLE OF CONTENTS 
TITLE PAGE .......................................................................................................... i 
SIGNATURE PAGE .............................................................................................. ii 
ACKNOWLEDGEMENTS .................................................................................... iii 
ABSTRACT .......................................................................................................... vi 
TABLE OF CONTENTS ...................................................................................... xii 
LIST OF TABLES ............................................................................................... xii 
LIST OF FIGURES ............................................................................................. xiii 
ABBREVIATIONS ............................................................................................... xv 
CHAPTER I : INTRODUCTION ............................................................................ 1 
Beclin 1 ............................................................................................................. 2 
Beclin 1-Interacting Proteins .......................................................................... 3 
Functions of Beclin 1 ...................................................................................... 7 
Beclin 1 and Cancer ...................................................................................... 18 
Rationale for the Thesis Project ................................................................... 24 
CHAPTER II : MATERIALS AND METHODS .................................................... 26 
Cell lines ....................................................................................................... 27 
Plasmids ....................................................................................................... 28 
Immunoblotting and antibodies .................................................................... 29 
Autophagic flux assay .................................................................................. 30 
ix
Glucose uptake and lactate production assay ............................................. 30 
Proliferation assays ...................................................................................... 31 
Soft agar colony formation assay ................................................................. 31 
Growth factor stimulation assays ................................................................. 32 
Quantitation of PI3P lipid .............................................................................. 33 
RNA extraction and real-time quantitative PCR (qRT-PCR) ........................ 33 
Invasion and migration assays ..................................................................... 34 
Immunofluorescence staining and imaging .................................................. 35 
Total Internal Reflection Fluorescence (TIRF)/Epi-fluorescence Structure-
illumination Microscopy (TESM) and image analysis ................................... 36 
Statistical Analysis ....................................................................................... 38 
CHAPTER III : CHARACTERIZATION OF AUTOPHAGY IN BREAST 
CARCINOMA CELLS ......................................................................................... 39 
Introduction .................................................................................................... 40 
Results ............................................................................................................ 43 
Triple-negative breast cancer cell lines have higher levels of basal 
autophagy than luminal breast cancer cell lines .......................................... 43 
Triple-negative MDA-MB-231 breast carcinoma cells are more sensitive to 
autophagy inhibition than luminal T47D cells ............................................... 48 
Genetic disruption of autophagy inhibits the anchorage-independent growth 
of MDA-MB-231 cells ................................................................................... 53 
Suppression of ATG5 but not Beclin 1 inhibits aerobic glycolysis ................ 55 
xDiscussion ...................................................................................................... 59 
CHAPTER IV : BECLIN 1 REGULATES EARLY ENDOSOME MATURATION 
AND GROWTH FACTOR RECEPTOR SIGNALING ......................................... 65 
Introduction .................................................................................................... 66 
Beclin 1 regulates growth factor receptor signaling ..................................... 69 
Beclin 1 in receptor degradation and signaling ............................................ 78 
Beclin 1 regulates growth factor receptor-dependent PI3KC3 activation and 
endosomal maturation .................................................................................. 81 
Beclin 1 negatively regulates invasion in breast carcinoma cell lines .......... 98 
Beclin 1 inversely correlates with phosphorylated AKT and ERK in human 
tumors .......................................................................................................... 98 
Discussion .................................................................................................... 104 
Acknowledgements ..................................................................................... 107 
CHAPTER V : DISCUSSION ............................................................................ 108 
Summary .................................................................................................... 109 
Impact of Beclin 1 loss in cancer ................................................................ 112 
Beclin 1 in human tumors ........................................................................... 116 
Regulation of Beclin 1 function by signaling pathway components ............ 118 
Role of Beclin 1 complexes in oncogenic signaling ................................... 119 
The impact of Beclin 1 on endosomal maturation ...................................... 121 
Targeting autophagy for cancer treatment ................................................. 123 
Overall significance .................................................................................... 124 
xi
APPENDIX : ANALYSIS OF EPIGENETIC REGULATION OF BECN1 IN 
BREAST CARCINOMA CELLS ....................................................................... 126 
BIBLIOGRAPHY ............................................................................................... 130 
 
 
xii
LIST OF TABLES 
Table 3.1. Molecular classification of breast carcinoma cell lines ...................... 44 
 
xiii
LIST OF FIGURES 
Figure 1.1. Beclin 1 protein and its complexes ..................................................... 4 
Figure 1.2. Regulators of autophagy .................................................................. 13 
Figure 3.1. Comparison of basal autophagy in breast carcinoma cell lines ....... 45 
Figure 3.2. Comparison of autophagic flux between MDA-MB-231 and T47D 
cells ..................................................................................................................... 47 
Figure 3.3. Comparison of aerobic glycolysis in breast carcinoma cell lines ...... 49 
Figure 3.4. The anchorage-dependent growth of MDA-MB-231 cells is more 
sensitive to autophagy inhibition when compared with T47D cells ..................... 51 
Figure 3.5. The anchorage-independent growth of MDA-MB-231 cells is more 
sensitive to autophagy inhibition when compared with T47D cells ..................... 52 
Figure 3.6. Autophagic flux in cells with suppression of ATG5 or Beclin 1 
expression ........................................................................................................... 54 
Figure 3.7. Autophagy facilitates anchorage-independent growth in MDA-MB-
231 cells .............................................................................................................. 56 
Figure 3.8. Suppression of ATG5, but not Beclin 1, expression inhibits glycolysis 
in MDA-MB-231 cells ........................................................................................... 58 
Figure 4.1. Beclin 1 depletion increases IGF-1R protein levels .......................... 70 
Figure 4.2. Beclin 1 regulates IGF-1-dependent signaling in MDA-MB-231 cells
 ............................................................................................................................ 72 
Figure 4.3. Beclin 1 regulates IGF-1-dependent signaling in MCF7 cells .......... 73 
Figure 4.4. Beclin 1 regulates IGF-1-dependent signaling in MCF10A cells ...... 74 
Figure 4.5. Beclin 1 regulates EGF-dependent signaling ................................... 75 
Figure 4.6. Ectopic expression of Beclin 1 decreases growth factor-dependent 
signaling .............................................................................................................. 76 
xiv
Figure 4.7. Rescue of Beclin 1 expression restores growth factor-dependent 
signaling to control levels .................................................................................... 77 
Figure 4.8. Regulation of EGFR degradation and signaling by Beclin 1 ............ 79 
Figure 4.9. Regulation of IGF-1R degradation and signaling by Beclin 1 ........... 80 
Figure 4.10. Regulation of receptor degradation and signaling by Beclin 1 is 
autophagy-independent ....................................................................................... 82 
Figure 4.11. Chemical inhibition of autophagy does not enhance AKT activation
 ............................................................................................................................ 83 
Figure 4.12. Beclin1 regulates growth factor signaling in early endosomes ....... 85 
Figure 4.13. Beclin1 regulates APPL1+ endosomes .......................................... 87 
Figure 4.14. Beclin1 regulates growth factor-dependent early endosome 
maturation ........................................................................................................... 89 
Figure 4.15. Beclin1 regulates growth factor-dependent transition to PI3P+ early 
endosomes .......................................................................................................... 90 
Figure 4.16. Rescue of Beclin 1 expression restores PI3P+ endosomes ........... 93 
Figure 4.17. Beclin 1 controls the maturation of early endosomes ..................... 94 
Figure 4.18. Beclin 1 controls PI3P levels .......................................................... 97 
Figure 4.19. Beclin 1 regulates breast carcinoma cell invasion .......................... 99 
Figure 4.20. Rescue of Beclin 1 expression decreases enhanced invasion in 
Beclin 1-depleted cells ...................................................................................... 100 
Figure 4.21. Inhibition of AKT signaling suppressed increased invasion in Beclin 
1-deficient cells .................................................................................................. 101 
Figure 4.22. Inverse correlation of Beclin 1 expression and AKT and ERK 
phosphorylation in human breast tumors .......................................................... 103 
Figure 5.1. Model of Beclin 1’s regulation of growth factor receptor signaling . 111 
Appendix Figure 1. Epigenetic regulation of Beclin 1 ...................................... 129 
xv
ABBREVIATIONS 
AMBRA1 Activating molecule in Beclin 1-regulated autophagy protein 1 or 
Autophagy/Beclin 1 regulator 1 
APPL  Adaptor protein with phosphotyrosine binding, pleckstrin 
homology domains and leucine zipper motif 
ATG  Autophagy related  
Bcl-2 B-cell lymphoma 2 
BECN1  Beclin 1 
BH3 Bcl-2 homology-3 
Bif-1 Bax-interacting factor-1 
CCD Coiled-coil domain 
CHX  Cycloheximide 
CQ Chloroquine 
ECD Evolutionarily conserved domain 
EEA1  Early endosome antigen 1 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
xvi
FYVE Fab1p, YOTB, Vac1p, EEA1 
GPCR  G-protein coupled receptor 
HOPS Homotypic fusion and vacuole protein sorting 
IGF-1  Insulin-like growth factor-1 
IGF-1R  Insulin-like growth factor-1 receptor 
LC3 Microtubule-associated protein 1 light chain 3 (MAP1LC3) 
MAPK Mitogen-activated protein kinase 
mRNA  Messenger RNA 
mTORC1/2 Mammalian/mechanistic target of rapamycin complex 1/2 
PI  Phosphoinositides 
PI3K Class I phosphatidylinositol 3-kinase 
PI3KC3  Class III phosphatidylinositol 3-kinase or Phosphatidylinositol 3-
kinase, catalytic subunit type 3 
PIKfyve  FYVE-containing phosphatidylinositol 3-phosphate 5-kinase 
PI3P  Phosphatidylinositol 3-phosphate 
p62/SQSTM1  Sequestosome 1 
ROS Reactive oxygen species 
xvii
Rubicon RUN domain, cysteine-rich domain containing, Beclin 1 
interacting protein 
shRNA  Short hairpin RNA 
siRNA  Small interfering RNA 
TESM  TIRF/epi-fluorescence structured illumination microscopy 
TIRF  Total internal reflection fluorescence 
TNBC Triple negative breast cancer 
UVRAG  UV radiation resistance-associated gene 
1CHAPTER I 
 
 
INTRODUCTION 
  
2Beclin 1 
Beclin 1 is a 60kDa highly conserved mammalian orthologue of the yeast 
Atg6/vacuolar protein sorting-30 (Vps30) protein. It was initially identified as a 
gene regulating vacuolar protein sorting in yeast (1). This discovery was followed 
by its recognition as an essential protein involved in the yeast autophagic 
process (2). The same year it was also identified in the mammalian system 
through a yeast two-hybrid screen. In mammals it was originally identified as a 
Bcl-2-interacting myosin-like coiled-coil protein (Beclin) with a potential role in the 
host defensive system as it provided protection to mice against Sindbis virus 
induced encephalitis (3). Subsequently, Beclin 1 was shown to promote 
autophagy and tumorigenesis in mammals (4). Since then Beclin 1 protein has 
been shown to play a role in numerous biological functions including autophagy 
stress adaptation, vesicular trafficking, cytokinesis, and cell death and it is 
essential for normal development (5). 
The Beclin 1 protein has three identifiable structural domains – the N-
terminal Bcl-2 homology-3 (BH3) domain, a coiled-coil domain (CCD) and a C-
terminal evolutionarily conserved domain (ECD) (5-7). It also has a short leucine-
rich nuclear export signal that is required for its cytoplasmic localization (8). 
Through these domains it interacts with various proteins and carries out its 
diverse functions (Figure 1.1A).  
3Beclin 1-Interacting Proteins 
One of the most important proteins in the Beclin 1 interactome is the lipid 
kinase Class III phosphatidylinositoI 3-kinase (PI3KC3; homologue of yeast 
Vps34). PI3KC3 phosphorylates phosphoinositides (PI) at the 3’ position of the 
inositol ring to generate phosphatidylinositol-3-phosphate (PI3P) (9). Beclin 1 
binds to PI3KC3 via its ECD and it is responsible for activation of this enzyme 
(10). Together with p150 (a homolog of yeast Vps15), Beclin 1 and PI3KC3 form 
a core complex. The myristoylated p150 subunit targets and anchors the core 
complex to the membrane (11). The core complex forms the central platform that 
recruits additional regulatory proteins to form multiple, distinct complexes that 
may explain the various cellular functions of Beclin 1. Two major complexes have 
been described in both yeast and mammals (Figure 1.1B) (12, 13).  
Complex I 
The macromolecular Complex I is comprised of the core complex bound to 
autophagy related 14-like (ATG14L; a homolog of yeast Atg14). It is also known 
as Beclin 1-associated autophagy-related key regulator (Barkor). ATG14L 
heterodimerizes with the CCD region of Beclin 1 and directs the complex to the 
site of autophagosome initiation - the endoplasmic reticulum (5, 14).  Complex I 
is required for initiation of the autophagic process.  Activating molecule in Beclin 
1-regulated autophagy protein (AMBRA1) is a Beclin 1-binding protein, which 
promotes interaction between Beclin 1 and PI3KC3 and thereby promotes auto-
4 
  
 
 
 
 
 
 
Figure 1.1. Beclin 1 protein and its complexes. 
(A) Schematic of Beclin 1 and its structural domains. NES, Nuclear export signal. (B) 
The two complexes formed by Beclin 1 and their known functions. Beclin 1, PI3KC3 and 
p150 form the core complex to which ATG14L or UVRAG binds to form complex I or II 
respectively. Figure adapted from Wirawan et. al. (5).  
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phagosome nucleation (15). 
Complex II 
The macromolecular Complex II is formed by recruitment of UV radiation 
resistance-associated gene (UVRAG; a homologue of yeast Vps38) to the core 
complex. Binding of UVRAG to the CCD region of Beclin 1 further enhances 
PI3KC3 activity (16).  Of note, the interaction of ATG14L and UVRAG with Beclin 
1 is mutually exclusive and distinguishes Complex I from Complex II (13, 17). 
The UVRAG protein regulates endosome-endosome and endosome-
autophagosome fusion, and hence vesicle maturation, by interacting with the 
homotypic fusion and vacuole protein sorting (HOPS)/class C-VPS complex and 
stimulating the endosomal fusion machinery (described ahead) (18). In yeast, 
Complex II is involved in vacuolar protein sorting but not autophagy. Deletion of 
the complex inhibits proper sorting of carboxypeptidase Y (CPY) from the pre-
vacuolar compartment (endosome) to the vacuole (12).  In mammals, Complex II 
was initially reported to play a role in the initiation and maturation of 
autophagosomes (16). However, recent studies have shown additional 
autophagy-independent functions for this complex including membrane trafficking 
events that regulate receptor degradation and cytokinesis (18, 19). Bax-
interacting factor-1 (Bif-1; also known as Endophilin B1 or SH3GLB1) is recruited 
to Complex II via UVRAG and it further enhances PI3KC3 activity (20). 
6Additional Beclin 1 regulatory interactions 
Beclin 1, and hence the two complexes, can also be regulated by 
additional interacting proteins. The anti-apoptotic Bcl-2 and Bcl-XL proteins bind 
to the BH3 domain of Beclin 1 and inhibit its interaction with PI3KC3.  This 
binding disrupts the core complex, thereby decreasing the lipid kinase activity 
and inhibiting autophagy (21, 22). Phosphorylation of Bcl-2 or Beclin 1 by stress-
activated c-Jun N-terminal protein kinase 1 (JNK) and death-associated protein 
kinase (DAPK), respectively, inhibits interaction of Bcl-2/Bcl-XL with Beclin 1 
resulting in activation of Beclin 1-mediated autophagy (23, 24). Similarly, High 
mobility group box 1 (HMGB1), in response to enhanced reactive oxygen species 
(ROS), binds to Beclin 1 leading to dissociation of the Beclin 1-Bcl-2 complex 
(25). In addition, the positive regulator of autophagy Ambra 1 can bind to both 
Beclin 1 and Bcl-2, as well as compete with Bcl-2 for binding to Beclin 1 thereby 
inducing autophagy (26). The Beclin 1-Bcl-2 interaction can also be disrupted by 
ubiquitination of the two proteins. TNF receptor associated factor 6 (TRAF6), in 
response to Toll-like receptor (TLR) signaling, ubiquitinates Beclin 1 to promote 
oligomerization of the protein, hence promoting autophagy (27).  
Rubicon (RUN domain and cysteine-rich domain containing, Beclin 1-
interacting protein), a negative regulator of autophagy, also reduces the kinase 
activity of the core complex and down regulates autophagy (28). Inhibition of 
Rubicon enhances autophagosome maturation and epidermal growth factor 
7receptor (EGFR) degradation, while over expression impairs these functions (29).  
Moreover, tagged Rubicon localizes with late endosome/lysosome markers, and 
partially with early endosomes, suggesting that this protein may mostly regulate 
Complex II (28, 30). 
AKT and EGFR have recently been reported to inhibit autophagy by 
negatively regulating Beclin 1. AKT phosphorylates Beclin 1, enhancing its 
interaction with 14-3-3 and vimentin intermediate filament proteins and resulting 
in inhibition of autophagy (31). Activation of EGFR also leads to inhibitory 
phosphorylation of Beclin 1. Active EGFR increases binding of Bcl-2 and Rubicon, 
and decreases binding of PI3KC3, to Beclin 1 resulting in down-regulation of 
autophagy (32).   
Functions of Beclin 1 
Beclin 1 is a key regulator of the lysosomal-dependent catabolic process 
called macroautophagy and it is one of the most studied mammalian autophagy 
proteins. In contrast, studies reporting autophagy-independent functions for 
Beclin 1 in mammals have only recently begun to emerge.  The role of Beclin 1 
(Atg6/Vps30) in vacuolar protein sorting in yeast has been documented since the 
1990s (1). Early studies showed that although human BECN1 can restore 
autophagy in atg6/vps30-disrupted yeast, it was unable to restore vacuolar 
protein sorting function (4). One of the reasons for this lack of rescue could be 
the difference in the protein sequences of the two orthologues that share only 
824.4% amino acid identity with 39.1% conservation (4). Nonetheless, 
identification of the two Beclin 1 complexes in mammalian systems (Complex I 
and II; described earlier), similar to yeast suggests autophagy-dependent and 
independent functions for Beclin 1 in mammals. Moreover, in contrast to other 
Atg gene-deficient mice (such as Atg5-/- and Atg7-/-) which survive birth but 
succumb to neonatal starvation, Becn1 null mice die early during embryogenesis 
(33-35). This finding further highlights that both autophagic and non-autophagic 
functions of Beclin 1 are likely important for the biological processes that it 
regulates.  
Autophagy 
Complex I and Complex II play a role in the initiation and maturation steps 
of autophagy, respectively (5).  Autophagy, which means “self-eating” in Greek, 
is an evolutionarily conserved, lysosome-mediated catabolic process utilized by 
cells to maintain homeostasis (36). A basal level of autophagy maintains 
intracellular protein and organelle quality by eliminating damaged, excess and 
abnormal organelles and protein aggregates. It is also a survival mechanism of 
the cell against various kinds of stress such as starvation, during which unwanted 
cytoplasmic material is recycled and adenosine triphosphate (ATP) molecules 
are synthesized (33, 37). Autophagy can also act as a defense system of the cell 
by degrading intracellular bacteria, viruses and parasites and thereby protecting 
it from pathogen invasion (38). 
9Autophagy has been categorized into three different types based on the 
mode of delivery of the cargo to the lysosomes (36):  
a. Chaperone-mediated autophagy (CMA): During CMA target substrates are 
recognized and translocated by chaperone protein Hsc70 (heat shock 
cognate 70) to the lysosomes where lysosomal-associated membrane protein 
type 2A (LAMP-2A) mediates their internalization into the lysosomal lumen 
(39-41). 
b. Microautophagy: In microautophagy cytoplasmic substrates are directly 
internalized into the lysosomes by invagination of the lysosomal membrane 
(42). 
c. Macroautophagy: This process involves sequestration of cytoplasmic 
material into double-membrane vesicles called autophagosomes which 
ultimately fuse with lysosomes to degrade the enclosed contents.  This thesis 
will focus on this form of autophagy.  
Macroautophagy (hereafter referred to as autophagy) can be induced by a 
number of stress signals such as starvation, oxidative stress and infection (43). 
Upon induction of autophagy a membrane structure known as a phagophore, or 
isolation membrane, starts forming around the cytosolic substrate. The isolation 
membrane elongates and eventually engulfs a portion of the cytosol in a double-
membrane sequestering vesicle called the autophagosome. The major 
membrane source for the nucleation and elongation of the phagophore are the 
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endoplasmic reticulum (ER) – Golgi intermediate compartment membranes (44, 
45). However, plasma membranes and cytoplasmic organelles, including the 
Golgi, endosomes and mitochondria have also been reported to contribute (46-
50). Once the autophagosome is formed, the outer membrane fuses with the late 
endosome to form the amphisome, or with the lysosome to form the 
autolysosome. Within the autolysosome the autophagosomal inner membrane 
and its contents are degraded by lysosomal proteases. 
Autophagy can be non-selective with no cargo-specificity or selective for 
its cargo. The type of cargo sequestered can further classify selective autophagy. 
For example, in mitophagy the autophagosome encapsulates and selectively 
eliminates damaged or excess mitochondria thereby maintaining mitochondrial 
quality and quantity (51, 52). Selective autophagy utilizes receptors and adaptors 
to recognize substrates and target them for degradation. For example the 
autophagic adaptor proteins p62/SQSTM1 (sequestosome 1), NDP52 and NBR1 
(neighbor of Brca1 gene) recognize and bind polyubiquitylated substrates and 
form aggregates (53-55). These adaptors also have an LC3-interacting region 
(LIR) via which they associate with the autophagy protein LC3 (also known as 
microtubule-associated protein 1 light chain 3, MAP1LC3; described ahead) 
anchored to the growing autophagosomal membrane. The autophagosome 
encapsulates and degrades the substrates. 
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Regulators of autophagy 
The initiation of the autophagic process is primarily controlled by mTOR 
complex 1 (mTORC1). This complex consists of a serine/threonine protein kinase 
mTOR (mammalian/mechanistic target of rapamycin), regulatory-associated 
protein of mTOR (Raptor), mammalian lethal with SEC13 protein 8 (mLST8), 
DEP domain-containing mTOR-interacting protein (DEPTOR) and Proline-rich 
AKT/PKB substrate of 40 kDa (PRAS40) subunits (56). mTORC1, which plays a 
central role in sensing nutrient and growth factor availability as well as oxygen 
and energy status of the cell,  is a negative regulator of autophagy (57, 58). 
Activation of upstream signaling pathways such as the class I 
phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated protein 
kinase (MAPK) pathway by growth factors activates mTORC1 resulting in 
repression of autophagy (59-61). 
Low nutrient conditions lead to an increase in the intracellular adenosine 
mono-phosphate/adenosine tri-phosphate (AMP/ATP) ratio, which in turn 
activates the cellular energy sensor AMP-activated protein kinase (AMPK) (62, 
63). Activated AMPK suppresses mTORC1 indirectly by phosphorylating and 
enhancing the activity of the negative regulator of mTORC1, tuberous sclerosis 2 
(TSC2) (64). Active AMPK also directly suppresses mTORC1 by phosphorylating 
and inactivating Raptor (65). AMPK can also directly promote autophagy by 
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phosphorylating and activating the ULK1 and Beclin 1-PI3KC3 complexes (see 
below) (66, 67).  
Since autophagy plays an important role in maintaining homeostasis and 
promoting survival it is highly regulated to control the level, timing and cargo 
specificity. Autophagy-related (Atg) proteins regulate this process. There are 
more than 30 autophagy-related proteins that have been identified in yeast, of 
which orthologues of more than half have been identified in higher eukaryotes. In 
the mammalian system the core molecular machinery regulating the initiation and 
elongation stages of the autophagic process include the following hetero-
oligomeric protein complexes. 
a. ATG1/ULK kinase complex: This autophagy initiator complex consists of the 
serine/threonine kinase ULK1/2 (Uncoordinated‐51‐like kinase 1 or 2; also 
known as Atg1 in yeast), FIP200 (FAK family kinase-interacting protein of 200 
kDa; also known as Atg17 in yeast), ATG13, and ATG101 subunits (68-70). 
This complex is negatively regulated by mTORC1. In the presence of 
nutrients, activated mTORC1 binds to the complex and phosphorylates ULK1 
and ATG13 to inhibit autophagosome formation. Upon nutrient depletion, the 
inhibitory binding of mTORC1 is released resulting in dephosphorylation of 
the complex. ULK1/2 then autophosphorylates itself, as well as ATG13 and 
FIP200 leading to activation of the complex (71-73). 
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Figure 1.2. Regulators of autophagy. 
Upon induction of autophagy by starvation, mTOR releases its inhibitory effect on the 
ULK1 complex, which together with the activated Beclin 1-PI3KC3 complex initiates 
autophagosome formation. The ATG12 and ATG8/LC3 conjugation systems are 
involved in the elongation and completion of the autophagosome membrane. The 
double-membraned autophagosome then fuses with the lysosome, where 
autophagosomal contents are degraded and recycled back to the cell. Figure adapted 
from Baehrecke, Nature reviews (74). 
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b. Beclin 1-Class III PI 3-kinase complex: This macromolecular complex 
consisting of Beclin1, PI3KC3, p150 and ATG14L subunits (Complex I), as 
mentioned earlier, is required for the nucleation of the isolation membrane 
(30). Beclin 1 activates PI3KC3 to generate phosphatidylinositol-3-phosphate 
(PI3P), which is essential for autophagosome formation. The ATG14L subunit 
mediates localization of the autophagy-specific PI3KC3 complex to the 
endoplasmic reticulum (ER) for phagophore nucleation (14). Recently, Russel 
et. al. reported that the PI3KC3 complex is regulated by ULK1. Upon 
inhibition of mTORC1 by amino acid withdrawal, Beclin 1 is phosphorylated 
by activated ULK1, resulting in increased lipid kinase activity of the complex 
and hence autophagy (75). As mentioned earlier, under low energy conditions 
due to glucose starvation, AMPK can directly phosphorylate Beclin 1 and 
activate Complex I (67).  
c. ATG12 and ATG8/LC3 conjugation systems: These two ATG7-dependent 
ubiquitin-like protein conjugation systems are required for the elongation and 
completion of the autophagosome. They mediate the lipidation of three 
subfamilies of proteins in mammals – MAP1LC3 (microtubule-associated 
protein 1 light chain 3; also known as LC3), GATE16 (Golgi-associated 
ATPase enhancer of 16kDa) and GABARAP (γ-aminobutyric acid receptor-
associated protein) (76). In the ATG12 conjugation system, the E1‐like 
enzyme ATG7, together with the E2-like enzyme ATG10, catalyze the 
conjugation of ATG12 to ATG5 (77, 78). The ATG12-ATG5 complex then 
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non-covalently binds to Atg16L1 forming a large multimeric complex (79). In 
the ATG8/LC3 conjugation system the cysteine protease ATG4 cleaves LC3 
at its carboxyl terminus forming cytosolic soluble LC3-I. Finally through a 
series of steps involving ATG7, ATG3 (E2-like enzyme) and the ATG12-
ATG5-ATG16 complex (E3-like ligase) LC3-I is conjugated to 
phosphatidylethanolamine (PE) to form LC3-II (80). This LC3-II form is 
anchored to the growing phagophore, as well as to the outer and inner 
membranes of autophagosomes. After autophagosome-lysosome fusion, 
LC3-II present on the inner membrane is degraded while that on the outer 
membrane can be recycled back by ATG4, which cleaves off the PE group 
(81). Since LC3-II remains associated with the phagophore, mature 
autophagosomes and autolysosomes, it is frequently used to monitor 
autophagy. 
Endocytosis 
Beclin 1 performs autophagy-independent functions as a part of Complex 
II. In addition to yeast, Beclin 1 has been reported to play a role in endocytic 
vesicle trafficking in other organisms including C. elegans and Drosophila. Bec-1, 
the orthologue of Beclin 1 in C. elegans mediates endocytic retrograde transport 
from endosomes to Golgi. In bec-1 mutants, MIG-14/Wntless cargo protein is 
misrouted from the endosome to the lysosome instead of the Golgi and degraded 
(82). Recently, Shravage et. al. also demonstrated that Atg6 is essential for fluid 
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phase endocytosis in Drosophila. Atg6-/- mutant drosophila cells showed 
negligible uptake of the endocytic tracer Texas Red-avidin (83).  In mammalian 
cells, a study performed by Thoresen et. al. reported that RNA-mediated 
silencing of subunits of Complex II (Beclin 1, PI3KC3, p150, UVRAG and Bif-1) in 
HeLa cells inhibited epidermal growth factor receptor (EGFR) degradation (19). 
In contrast, depletion of Atg14L had no effect, implicating a role for Complex II in 
endocytic receptor degradation. However, these results were contrary to results 
from an earlier study which reported that inhibiting BECN1 suppressed 
autophagy, but not EGFR degradation (84).  
The Complex II subunit UVRAG, which is recruited to Complex II by Beclin 
1, also regulates endocytic trafficking by mediating endosome-endosome fusion 
to promote maturation (18). Key players of the endocytic pathway are a subfamily 
of small GTPases, the Rab GTPases. Rabs can recruit specific cytoplasmic 
effector proteins and tethering factors to the endosomal membranes and thereby 
regulate trafficking (85). Rab5 associates with early endosomes and recruits the 
effector protein PI3KC3 to generate PI(3)P from phosphoinositides (86). PI(3)P 
mediates the recruitment of effector proteins containing PI(3)P-binding FYVE 
(Fab1p, YOTB, Vac1p, EEA1) and PX (Phox homology) domains to endosomal 
membranes (87, 88). This recruitment facilitates vesicular fusion and sorting 
events and is required for progression of endocytosis. Subsequently, Rab5 
undergoes a process called Rab conversion during which Rab7 accumulates at 
the endosomal membrane with simultaneous removal of Rab5 (89). This 
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conversion drives the maturation of early endosomes to late endosomes. The 
PI3KC3 complex present on the endosomal membrane, in turn recruits UVRAG 
which activates the class C-VPS/HOPS (homotypic fusion and vacuole protein 
sorting) complex (18). HOPS is a tethering factor that also acts as a guanine 
nucleotide exchange factor (GEF) for Rab7. It catalyzes the exchange of GDP for 
GTP and activates Rab7. Stimulation of Rab7 activity promotes endosomal 
fusion and subsequent cargo degradation in the lysosome (18). However, Rab7 
activation can be inhibited by a negative regulator of autophagy - Rubicon. 
Rubicon sequesters UVRAG making it unavailable for binding to C-VPS/HOPS, 
thereby preventing progression of endocytosis (29).  
Cytokinesis 
Complex II has also been reported to be involved in regulating 
cytokinesis(19). Suppression of components of the UVRAG-containing Complex 
II was reported to arrest the process. Moreover, both UVRAG and Bif-1, but not 
ATG14L, colocalize to the midbody (a sub-cellular structure present between 
dividing daughter cells implicated in controlling cytokinesis) (19). This study 
implicates that Complex II may contribute to maintaining chromosome number 
and stability.  
18
Beclin 1 and Cancer 
Autophagy is a self-eating process involved in degradation of excess and 
damaged macromolecules and it can be both cytoprotective and cytopathic.  
Uncontrolled autophagy can lead to cannibalistic, non-apoptotic cell death 
termed Type II programmed cell death, or autophagic cell death, while inefficient 
autophagy leads to the inability of cells to clear damaged cellular debris (90, 91). 
Dysfunctional autophagy has been implicated in various human diseases 
including cancer (92). Beclin 1 (BECN1) was the first autophagy gene reported to 
link autophagy to cancer (4).The BECN1 gene is located on human chromosome 
17q21 and it is monoallelically deleted in 40% of prostate, 50% of breast and 
75% of ovarian cancers (93). Its heterozygous disruption causes spontaneous 
tumorigenesis in mice (35, 94). These mice are prone to mammary hyperplasia 
and develop increased number of lymphomas, hepatocellular carcinomas and 
lung adenocarcinomas as compared to age-matched littermates. On the other 
hand, overexpression of Beclin 1 inhibits in vitro cancer cell proliferation and 
clonigenicity as well as tumor formation in nude mice (4). Comparison of BECN1 
expression in matched normal breast and breast carcinoma tissue from patients 
with invasive sporadic breast carcinoma showed lower expression levels in 
breast carcinoma samples compared to their normal counterparts (4).  
Despite the above mentioned connection to cancer, a recent study by 
Laddha et. al. questioned the tumor-suppressive function of Beclin 1 (95). In their 
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analysis of human tumor sequencing data from The Cancer Genome Atlas 
(TCGA), they found no evidence for mutation or focal loss of BECN1 gene. 
Mutational analysis revealed that BECN1 deletion did not occur alone but in 
conjunction with the proximally located tumor suppressor gene BRCA1 (breast 
cancer 1, early onset) (95). This new study therefore suggests that changes in 
Beclin 1 protein expression in tumors likely arise through epigenetic or 
transcriptional modifications. In humans, aberrant DNA methylation of the 
promoter and intron 2 of the BECN1 gene have been reported in tumors with 
decreased Beclin 1 expression (96). Moreover, a reduction in Beclin 1 protein 
expression has been reported to be associated with poor prognosis in a number 
of cancers (97, 98).  
Since Beclin 1 is a well-established regulator of autophagy, the tumor 
suppressive function of Beclin 1 has mostly been attributed to its regulation of the 
autophagic pathway. However, the role of autophagy in cancer is quite complex 
and may be stage and context dependent. It is considered as a “double-edged 
sword”, with both tumor promoting and tumor suppressing abilities. The current 
consensus is that autophagy suppresses early oncogenic transformation but can 
promote progression of established tumors. 
Autophagy as a tumor suppressor 
Autophagy plays a tumor suppressive role by eliminating protein 
aggregates and damaged organelles and thereby oxidative stress (99). Under 
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normal metabolic conditions mitochondria produce reactive oxygen species 
(ROS). The presence of damaged mitochondria elevates ROS levels, which 
triggers mitophagy (100). Dysfunction of this process leads to accumulation of 
damaged mitochondria resulting in excess ROS production (101). The increased 
intracellular ROS levels further increases metabolic stress in autophagy-defective 
cells causing DNA damage and genomic instability which can drive tumor 
formation (99). Quenching ROS with its scavenger N-acetyl cysteine (NAC) 
delays promotion of aneuploidy in autophagy-impaired Becn1+/- cells. Thus, the 
inability of autophagy-deficient cells to suppress ROS production leads to 
chromosomal instability (99). 
In cells with intact autophagy, damaged proteins and organelles are 
targeted for degradation in the autophagosome by the autophagy cargo-receptor 
p62/SQSTM1 (53). This receptor is also degraded during the process. Allelic loss 
of Becn1 increases susceptibility to metabolic stress resulting in accumulation of 
p62, damaged mitochondria and endoplasmic reticulum chaperones in vitro and 
in vivo (99). Over-expression of p62 in Becn1+/- cells results in p62 aggregate 
accumulation, elevated ROS production and DNA damage which promotes 
tumorigenesis while suppression of p62 reduced DNA damage induction. 
Autophagy-deficient Atg5-/- cells also show similar defects (99). These results 
indicate that impaired p62 elimination due to defective autophagy leads to 
genomic instability and tumorigenesis (99). Persistent p62 can also activate the 
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transcription factor Nrf2 (nuclear factor, erythroid 2-like 2) resulting in 
transcription of genes that promote angiogenesis and cell survival, both of which 
are known to facilitate tumor progression (102).   
In established tumors, regions of the tumor microenvironment are nutrient 
depleted and hypoxic due to increased proliferation rate and insufficient 
vascularization. Autophagy helps apoptosis-resistant cells in these ischemic 
regions survive metabolic stress (103). Suppression of either Beclin 1 or atg5 in 
Bcl-2-expressing apoptosis-resistant cells reduces autophagy induction and 
impairs survival in ischemia. Moreover, Becn1+/- apoptosis-resistant tumors also 
show a prevalence of necrosis (103). Tumor necrosis is associated with 
inflammatory cell infiltration, which produces cytokines and chemokines and 
promotes angiogenesis, tumor progression and metastasis (103-105). Thus, 
autophagy can also suppress tumor growth by restricting necrotic death of 
metabolically stressed, apoptosis-resistant tumor cells, thereby preventing 
macrophage infiltration and chronic inflammation that can promote tumor growth 
and metastasis.  
 The role of autophagy as a tumor suppressive process is further 
supported by genetic inhibition of some ATG proteins other than Beclin 1. 
Frameshift mutations, which would lead to synthesis of truncated proteins and 
therefore impaired autophagy, have been reported in ATG2B, ATG5 and ATG9B 
genes in gastric and colorectal cancers with microsatellite instability (106). 
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Knockout of another autophagy gene Atg4C increased the susceptibility of mice 
to develop fibrosarcomas induced by chemical carcinogens as compared with 
their wild-type littermates (107). Mice with systemic mosaic deletion of Atg5 and 
liver-specific knockout of Atg7 develop benign liver adenomas. However, these 
hepatomas do not progress to hepatocellular carcinoma suggesting that 
autophagy may be required for tumor progression (108).  
Autophagy as a tumor promoter 
In established tumors, autophagy can promote tumor growth by helping 
tumor cells adapt to the poorly vascularized, hypoxic tumor microenvironment 
(103, 109). It can help tumor cells survive in this metabolically stressful 
environment by supplying nutrients and maintaining energy homeostasis. In a 
study done by Yang et. al. autophagy has been reported to be required for 
tumorigenic growth of pancreatic cancer (110). They also show that pancreatic 
ductal adenocarcinoma (PDAC) cell lines have elevated basal autophagy and 
their growth can be suppressed by inhibiting this process. Both chemical and 
genetic inhibition of autophagy led to robust tumor regression and prolonged 
survival in pancreatic cancer xenografts and genetic mouse models (110).  
Work done by Fung et. al. showed that inhibition of autophagy by 
depletion of Beclin 1, ATG5 or ATG7 enhanced apoptosis induced by 
detachment from extracellular matrix (111). Defective autophagy also decreased 
clonogenic survival of cells that were re-plated after detachment-induced 
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apoptosis, also known as anoikis (111).  Since detachment of cells from the 
extracellular matrix is a critical step for dissemination and metastasis of tumor 
cells, autophagy may also promote metastasis by helping epithelial cells survive 
anoikis. Moreover, activation of autophagy can help cancer cells adapt to 
therapeutic insults making them resistant to anti-cancer treatment. Use of 
autophagy inhibitors or knockdown of Atg5 or Atg7 increases therapeutic cell 
killing, indicating autophagy contributes to acquired chemo-resistance of tumor 
cells (112).  
Autophagy-independent role for Beclin 1 in cancer 
Non-autophagic functions of Beclin 1 have been relatively understudied in 
the context of cancer. As stated earlier, mice with systemic mosaic deletion of 
Atg5 and liver-specific knockout of Atg7 develop only benign liver adenomas with 
no other neoplasms (108). Moreover, inhibition of p62 in these mice reduced 
these hepatomas indicating the possible cause to be the accumulation of p62 in 
the stressed liver. On the other hand, Becn1+/- mice develop tumors in multiple 
organs including the liver suggesting a potential autophagy-independent role for 
Beclin 1 in cancer (35, 94). 
In contrast with Atg14L (Complex I), which has not been shown to have 
tumor suppressor activity, UVRAG and Bif-1 (Complex II) have both been 
implicated as tumor suppressors. UVRAG, a positive regulator of PI3KC3 
complex, is monoallelically mutated at a high frequency in human colon 
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carcinomas with microsatellite instability (113). Interestingly, colon cancer cell 
lines with UVRAG mutations did not exhibit a decrease in autophagy. Moreover, 
expression of wild-type UVRAG in a human colon cancer cell line, HCT116 (with 
reduced levels of endogenous UVRAG), suppressed tumorigenicity in nude mice 
(16). Frameshift mutations in the UVRAG gene have also been reported in 
gastric carcinoma with microsatellite instability (114). Bif-1, which interacts with 
Beclin 1 through UVRAG, is another protein that enhances the Beclin 1-PI3KC3 
complex activity (20). Bif-1 is frequently deleted or down-regulated in a number of 
cancers including gastric, prostate, colorectal and pancreatic cancers (115-118). 
Allelic loss of Bif-1 promotes chromosomal instability and accelerates the 
development of Myc-induced lymphoma (119). Bif-1-/- mice have a higher 
frequency of developing spontaneous tumors, specially lymphoma, when 
compared to wild-type mice (20).  Taken together these results support that 
autophagy-independent functions of Beclin 1 are likely to play a role in cancer. 
Rationale for the Thesis Project 
In recent years, emerging studies have revealed the existence of 
autophagy-independent functions for mammalian Beclin 1. To date, the tumor 
suppressor function of Beclin 1 has been ascribed primarily to its role in 
autophagy and the impact of alternate functions of Beclin 1 on cancer and its 
mode of action have yet to be demonstrated. Although Beclin 1 and its binding 
partners in Complex II have been shown to be involved in endocytic receptor 
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trafficking, the contribution of Beclin 1 to this pathway is still unclear (19). 
Additionally, the report refuting the involvement of Beclin 1 in EGFR degradation 
increases the ambiguity about the contribution of Beclin 1 to this regulatory 
pathway (84). For my thesis research work I sought to determine the role of 
Beclin 1 in breast cancer and focused on understanding its regulation of growth 
factor receptor endocytosis. The endocytic pathway modulates the strength and 
duration of growth factor signaling by regulating the downregulation and recycling 
of growth factor receptors. Deregulation of receptor endocytosis could lead to 
aberrant receptor signaling and contribute to the development and progression of 
cancer. Hence understanding the mode of action of Beclin 1 in regulating 
receptor endocytosis would help us better appreciate the potential impact of non-
autophagic functions of Beclin 1 in cancer. 
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CHAPTER II 
 
 
MATERIALS AND METHODS 
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Cell lines 
MDA-MB-231, T47D and MCF7 human breast carcinoma cell lines were 
obtained from ATCC. SUM159,SUM149 and MCF10A cell lines were a gift from 
Dr. A. Mercurio (University of Massachusetts Medical School). MDA-MB-231 and 
T47D cells were maintained in RPMI 1640 and MCF7 cells were cultured in 
DMEM (all from GIBCO®). Media was supplemented with 10% fetal calf serum. 
SUM159 and SUM149 cells were cultured in F12 Nutrient mixture (Ham) 
containing 5% FBS, 25mM HEPES, 5 µg/ml Insulin and 1 µg/ml hydrocortisone. 
MCF10A cells were grown in DMEM/F12 (1:1) containing 5% horse serum, 20 
ng/ml EGF, 10mM HEPES, 10 µg/ml insulin, 0.5 µg/ml hydrocortisone and 100 
ng/ml Cholera toxin.  
Stable knockdowns were generated using lentiviral vectors from Open 
Biosystems, containing small hairpin RNAs (shRNA) targeting human BECN1 
(Clone IDs: TRCN0000033550, TRCN0000033552) human ATG5 (Clone IDs: 
TRCN0000151963, TRCN0000150645) and GFP, or a scrambled shRNA. After 
infection, cells were selected for stable expression with puromycin (2 µg/ml). For 
over-expression and Beclin 1 rescue, Beclin 1 was expressed transiently using a 
lentiviral vector containing Flag-Beclin 1. 48 hours post-infection the cells were 
stimulated with IGF-1 (100 ng/ml) in media containing 0.1% BSA (no prior 
starvation) for the time periods indicated in the figures. 
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Plasmids 
Lentiviral Flag-Beclin 1 was constructed by cloning Flag-Beclin 1 (Dr. 
Stephen Doxsey, University of Massachusetts Medical School) into the EcoRI 
cloning site of the lentiviral expression vector pCDH-CMV-MCS-EF1-copGFP 
(System Biosciences). In order to rescue Beclin 1 expression, four silent 
mutations were introduced into the shRNA-targeting region of BECN1 using the 
QuikChange® site-directed mutagenesis kit (Stratagene). The primers used for 
mutagenesis were:  
Forward 5’-CTGAAATTTCAGAGATACCGACTgGTgCCTTACGGAAACCATTC-3’ 
Reverse 5’-CAGATATGAATGGTTTCCGTAAGGcACcAGTCGGTATCTCTGGAG-3’ 
Forward 5’-CAGAGATACCGACTgGTgCCaTAtGGAAACCATTCATATC-3’ 
Reverse 5’-GATATGAATGGTTTCCaTAtGGcACcAGTCGGTATCTCTG-3’ 
For imaging experiments cells were transfected with EGFP-FYVE, 
TagRFP-T-APPL1 and/or TagRFP-T-Beclin 1 using Cell Line Nucleofector® Kit V 
(Lonza Cologne AG, Germany) as per the manufacturer’s protocol. EGFP-FYVE 
containing the FYVE domain of human SARA (589-656) and TagRFP-T-APPL1 
were a gift from Dr. Silvia Corvera (University of Massachusetts Medical School) 
and have been described previously (120). TagRFP-T-BECN1 plasmid was 
generated by cloning Flag-Beclin 1 in frame with TagRFP-T at the N-terminus of 
the Flag-Beclin 1 protein using the EcoRI cloning site (121).  
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Immunoblotting and antibodies 
Cells were extracted at 4oC for 10 minutes in a 20 mM Tris buffer, pH 7.4, 
containing 0.15 M NaCl, 1% NP-40, 10% Glycerol, 1 mM sodium orthovanadate, 
10 mM NaF and protease inhibitors (Complete Mini Tab; Roche). Cell extracts 
containing equivalent amounts of total protein were resolved by SDS-PAGE, 
transferred to nitrocellulose filters. Nitrocellulose filters were blocked for 1 h in 50 
mM Tris buffer (pH 7.5) containing 0.15 M NaCl, 0.05% Tween 20, and 5% 
(weight/volume) dry milk/Bovine serum albumin and then incubated overnight at 
4oC in the same buffer containing the respective primary antibodies. This was 
followed by three 15 minute washes with 50 mM Tris buffer (pH 7.5) containing 
0.15 M NaCl and 0.05% Tween 20. The filters were then incubated for 1 h in 
blocking buffer containing peroxidase-conjugated secondary antibodies. After 
three more 15 minute washes with 50 mM Tris buffer (pH 7.5) containing 0.15 M 
NaCl and 0.05% Tween 20, bands were detected by chemiluminescence using a 
ChemiDoc XRS+ system (BioRad Laboratories). Band intensities were quantified 
by densitometry using Image Lab (Beta 1) (Bio-Rad Laboratories). 
Antibodies used for immunoblotting included: LAMP-1 (Catalog # H5G11; 
Santa Cruz Biotechnology), GAPDH (Catalog # A300-642A; Bethyl Laboratories), 
actin (Catalog # A2066; Sigma) and tubulin (Catalog # T5168; Sigma). All other 
antibodies were purchased from Cell Signaling Technology, Inc: pIGF-1Rβ 
(Y1135/1136) (Catalog # 3024), IGF-1Rβ (Catalog # 3027), pEGFR (Y1086) 
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(Catalog # 2220), EGFR (Catalog # 4267), pAKT(S473) (Catalog # 9271), 
pAKT(T308) (Catalog # 2965), AKT (Catalog # 9272), pERK1/2 (T202/Y204) 
(Catalog # 9106), ERK1/2 (Catalog # 9102), Beclin 1 (Catalog # 3738), ATG5 
(Catalog # 2630) and LC3B (Catalog # 3868).  
Autophagic flux assay 
MDA-MB-231 cells expressing shGFP, shATG5 or shBECN1 after two 
washes with 1X PBS, were incubated in either RPMI 1640 supplemented with 
10% fetal bovine serum or Hank’s Balanced Salt Solution (GIBCO®), with and 
without 25 µM Chloroquine diphosphate (Catalog # C6628; Sigma) for 4 and 8 
hours. Cells were extracted as described above. 
Glucose uptake and lactate production assay 
Cells grown in triplicates in 12-well plates were serum-starved in 1ml 
media containing 0.1% BSA for 24 hours. After the 24-hour incubation 
conditioned media was collected and glucose and lactate present was assayed 
using the Glucose (GO) assay kit (Catalog # GAGO20; Sigma) and lactate kit 
(Trinity Biotech). The amount of cellular protein present in each well was also 
quantified by Bradford assay. Glucose uptake and lactate production were 
calculated and expressed as a rate measurement (mM/mg of total protein/hour) 
(122).  
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Proliferation assays 
Proliferation was monitored using the MTT colorimetric assay. In this 
assay cleavage of the yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) to purple colored formazan is measured. 
5000 cells were plated in each well of a 48-well culture plate. To assess 
proliferation, cells were seeded in multiple plates and one plate was used per day. 
On the day of the assay, media from one plate was replaced with 400 µl fresh 
media containing 0.5mg/ml MTT reagent and incubated at 37oC for 4 hours. 
Following incubation, the MTT containing medium was discarded and cells were 
solubilized in DMSO for 10 minutes at 37oC. Absorbance was measured at 595 
nm. Proliferation was determined by the absorbance of the dye taken up by the 
cells. To examine the impact of autophagy inhibition on proliferation rates, cells 
were treated with 0 µM, 6.25 µM or 25 µM of Chloroquine diphosphate starting at 
Day 0.  
Soft agar colony formation assay 
Wells of a 6-well plate was coated with 0.75% agar to prepare a base. 
After the bottom agar layer solidified, 2500-3000 cells resuspended in pre-
warmed 0.3% agar were layered on top. 0.5 ml of media was added after the top 
agar layer containing the cells also solidified. Cells were plated in duplicates. 
Media was changed every 2 days. Images were taken of 5 separate fields per 
well after 20 days of incubation. The number and size of colonies were quantified 
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using ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2014). To examine the 
impact of autophagy inhibition on anchorage-independent growth, MDA-MB-231 
and T47D cells plated in soft agar were treated with 0 µM, 12.5 µM or 25 µM of 
Chloroquine diphosphate. 
Growth factor stimulation assays 
Cells were serum-starved for either 2 hours or overnight in media 
containing 0.1% BSA and then stimulated with IGF-1 (100 ng/ml) or hEGF 
(50ng/ml) for the time periods indicated in the figures. To inhibit internalization, 
cells were incubated with 10 µg/ml of Chlorpromazine HCl (Catalog # C8138; 
Sigma) for 1 hour prior to and during stimulation. For receptor degradation 
assays, 50 µg/ml of cycloheximide (Catalog # C4859; Sigma) was added to 
serum-starved cells 1 hour prior to the addition of growth factors. To examine the 
impact of AKT inhibition on receptor degradation, cells were treated with 0.5 µM 
MK2206 (Catalog # S1078; Selleck Chemicals) or DMSO together with 
cycloheximide 1 hour prior to growth factor stimulation. Cells were extracted as 
described above. To examine the effect of chemical inhibition of autophagy, cells 
were treated with 30 µM Chloroquine diphosphate for 4 hours and then extracted.  
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Quantitation of PI3P lipid 
1x106 cells were plated in 10cm plates and serum starved overnight and 
then stimulated with IGF-1 (100ng/ml) or EGF (50ng/ml) for the indicated time 
periods. PI3P lipid levels were measured using the PI3P Mass ELISA Kit 
(Catalog # K-3300) according to manufacturer’s instructions.  
RNA extraction and real-time quantitative PCR (qRT-PCR) 
Total mRNA was extracted and purified from cells using the RNeasy kit 
(Qiagen) and converted into cDNA using Superscript® II Reverse Transcriptase 
(Invitrogen). SYBR® Green RT-PCR reagents (Applied Biosystems) were used 
to quantify gene expression. IGF1R and BECN1 expression were normalized to 
human actin.  
Primers used:  
IGF1R forward 5’-CAAGTTGAGGATCAGCGAGA-3’;  
IGF1R reverse 5’-AACACAGGATCTGTCCACGA-3’;  
BECN1 forward 5’-CTCTGGCCAATAAGATGGGT-3’;  
BECN1 reverse 5’-CGGCAGCTCCTTAGATTTGT-3’;  
actin forward 5’-TGAGCGCGGCTACAGCTT-3’;  
actin reverse 5’-TCCTTAATGTCACGCACGATTT-3’. 
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Invasion and migration assays 
For migration assays, 0.6ml of DMEM containing 15 µg/ml collagen 
(PureCol® Bovine Collagen Solution, Type I, Catalog # 5005-B; Advanced 
BioMatrix) was added to the bottom of each 6.5 mm Transwell chamber (8 µm 
pore size; Costar), and the filters were coated for 1 hour at 37oC. Cells were re-
suspended in DMEM containing 0.1% BSA and 104 cells were added to the top 
well of each Transwell chamber. After 4.5 hours, cells that had migrated to the 
lower surface of the filters were fixed in methanol for 10 mins. The fixed 
membranes were mounted onto glass slides using Vectashield mounting medium 
containing 4’, 6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA).  
Matrigel invasion assays were performed as described previously (122). 
104 cells were added to the top well of each Transwell chamber and allowed to 
invade through the Matrigel (Catalog # 356237; BD Biosciences) for 4.5 hours. 
Cells that had invaded to the lower surface were fixed and quantified as 
described above for migration assays. For Beclin 1 rescue experiments, cells 
were infected with shBECN1-resistant Flag-Beclin 1 48 hours prior to the assay. 
For inhibitor studies, cells were pre-incubated with 5 µM AG1024 (Catalog # 
S1234; Selleck Chemicals) for 16 hours or with 0.5 µM MK2206 for 1 hour prior 
to the assays. Inhibitors were also present in the upper and lower wells of the 
Transwell chamber during the assays. Migration and invasion were quantified by 
counting the number of stained nuclei in five separate fields of each Transwell 
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membrane using ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of 
Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2014). 
Immunofluorescence staining and imaging 
Cells were plated on glass coverslips, serum-starved overnight and 
stimulated with IGF-1 (100 ng/ml) for the time periods indicated in the figures. 
Cells were washed with 1X DPBS (GIBCO®) before fixing in 4% formaldehyde 
for 30 mins. Fixed cells were blocked for an hour in 1X DPBS containing 3% BSA 
and 0.5% Triton X-100 and then incubated in the same buffer containing primary 
antibody for 1 hour. Following three washes with 1X DPBS, cells were incubated 
in secondary antibody (Alexa Fluor 488 or Alexa Fluor 660 from Molecular 
Probes; Life Technologies Corporation) diluted in blocking buffer for 1 hour. After 
washing, coverslips were mounted on glass slides using Vectashield mounting 
medium containing DAPI. Stained cells were imaged using a Zeiss LSM700 
confocal microscope with a 63X, 1.4 NA Plan Apochromat oil objective equipped 
with an AxioVision Imager.Z2 camera. Zen 2012 software was used to acquire 
the images. Number of APPL1 puncta in each cell was quantified using ImageJ 
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, 
USA, http://imagej.nih.gov/ij/, 1997-2014). 
Antibodies used for immunofluorescence staining included APPL1 
(Catalog # 3858) and EEA1 which was generated as described previously (121). 
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Total Internal Reflection Fluorescence (TIRF)/Epi-fluorescence Structure-
illumination Microscopy (TESM) and image analysis 
The TESM Optical System imaging hardware and software have been 
described previously (121). It is a custom-built microscope system that 
simultaneously combines Total Internal Reflection Fluorescence and wide-field 
epi-fluorescence modes. The latter incorporates structured illumination for fast 
optical sectioning and enhanced spatial resolution. Two diode-pumped solid-
state 100mW lasers (Cobalt) produced 491 nm and 561 nm light while a 120mW 
diode laser (Blue Sky Laser) produced 660 nm light. The system uses a modified 
Olympus IX71 inverted microscope. The TIRF illumination is adjusted such that it 
passes through the edge of an Olympus TIRF 60X objective with an NA of 1.49 
at an angle so as to visualize 100-200nm from the coverslip. Light form the 
fluorophores was collected and relayed onto a 1004x1002 Andor iXon 885 
EMCCD camera, binned by 2. A Physik Instruments PIFOC was used for fine 
focus control. Focus stabilization was performed by pgFocus consisting of 
software and electronics developed by the Biomedical Imaging Group at UMass 
(http://big.umassmed.edu/wiki/index.php/PgFocus). 
Cells were transfected with plasmids indicated in the figures using Cell 
Line Nucleofector® Kit V (Lonza Cologne AG, Germany) as per the 
manufacturer’s protocol. Transfected cells were plated on glass coverslips and 
grown for an additional 48 hours.  For imaging, cells were incubated at 35oC in 
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KRH buffer (125 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 25 mM 
HEPES pH 7.4, 2 mM sodium pyruvate and 0.5% BSA). Cells transfected with 
TagRFP-T-APPL1 alone were stimulated with Alexa-Fluor-488 EGF complex 
(Invitrogen) and cells co-transfected with EGFP-FYVE and TagRFP-T, TagRFP-
T-BECN1 or TagRFP-T-APPL1 were stimulated with biotinylated EGF (Catalog # 
E3477; Life Technologies) complexed with streptavidin DyLight 650 conjugate 
(Catalog # 84547; Thermo Scientific). EGF was washed out after 8 minutes of 
stimulation and replaced with KRH buffer. Cells were imaged for another 12 
minutes (approximately). For Figure 4.14 the time series protocol used lasers 
emitting 491 nm (EGF) and 561 nm (TagRFP-T-APPL1) while for Figure 4.15 – 
4.17 the time series protocol used lasers emitting 491 nm (EGFP-FYVE/EGF), 
561 nm (TagRFP-T-APPL1/ TagRFP-T-BECN1) and 660 nm (EGF/EEA1).  
Quantitative TIRF image analysis was performed as described previously 
(121, 123). Time series raw images were first corrected by subtracting the 
background fluorescence followed by performing a temporal running average of 
three time points to reduce noise with negligible effect on the data. In order to 
quantitatively analyze structured fluorescence (i.e. vesicles) without interference 
from diffuse fluorescence, images were convolved with a small, 2D Gaussian 
spot (σ = 150 nm) that preserved the mean intensity and a larger, 2D Gaussian 
spot (σ = 300 nm) that estimated and subtracted the local background. A binary 
masking image was generated by visually thresholding the image so as to only 
select pixels belonging to the fluorescent structures (which were given a value of 
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one) and eliminate noise (pixel value was set to zero). Masked images were 
generated by multiplying the binary mask with the original image to display 
structures with intensity greater than the average local background. Co-
localization was determined by two-way overlap of the masked images of each 
label and co-localized pixels are shown as white or as indicated by the 
accompanying color wheel. Co-localization values have been reported as percent 
of pixels of a label that co-localized with another label. Co-localization seen when 
pixel-rich regions were rotated 180 degrees relative to each other have been 
labeled spurious. 
Epifluorescence images were generated from structured illumination data 
sets according to methods described previously (121). Raw images were 
processed as described above and binary masked images were used for 
quantifying the number of EGFP-FYVE puncta (between 10-10000 pixel size) in 
each cell (Figure 4.16) and for quantitative analysis of co-localization between 
labels (Figure 4.17). 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6. Statistical 
analyses between two groups were performed using the two-tailed unpaired 
Student’s t-test. Data are represented as mean ± standard error unless 
mentioned otherwise. A p value of 0.05 was considered statistically significant.  
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CHAPTER III 
 
 
CHARACTERIZATION OF AUTOPHAGY IN BREAST 
CARCINOMA CELLS  
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Introduction  
Autophagy is a lysosome-dependent degradation process that plays a 
major role in maintaining cellular homeostasis by degrading and recycling 
damaged and excess cytoplasmic components. It is also an adaptation process 
of the cell, activated under conditions of stress. Deregulation of autophagy has 
been implicated in the development of various diseases including cancer, 
neurodegeneration and inflammation (92).  
The role of autophagy in cancer has been proposed to be both preventive 
and promoting (90). By eliminating aggregates of damaged proteins and 
organelles, autophagy prevents excess production of reactive oxygen species 
(ROS), oxidative stress and genome instability, thereby impeding tumor initiation. 
Autophagy can also prevent necrosis and a subsequent tumor promoting 
inflammatory response. Nonetheless, since it supports cell survival under various 
forms of stress, autophagy could also promote tumorigenesis by helping cancer 
cells survive in the hypoxic, nutrient-deprived tumor microenvironment. In 
addition, induction of autophagy can help protect cells from death due to 
extracellular matrix detachment or anoikis, which is required for dissemination of 
tumor cells to other parts of the body. Finally, autophagy can also provide 
resistance to chemotherapy. The function of autophagy in cancer is therefore 
quite complex and still under investigation, with the general consensus being that 
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this process prevents cancer initiation but can promote progression of 
established tumors. 
Emerging investigations have revealed that the role of autophagy in 
cancer may also be context specific. The requirement of autophagy for various 
cancer types could be different depending on their metabolic requirements and 
activated oncogenic pathways. Aberrant activation of the PI3K pathway 
commonly found in many cancers activates the negative regulator of autophagy, 
mTORC1, thereby inhibiting autophagy (124). In contrast Ras transformation can 
upregulate basal autophagy (125). Interestingly, the tumor suppressor p53 that is 
frequently mutated in human cancers plays a dual role in autophagy. Nuclear p53 
induces autophagy while cytoplasmic p53 represses the process (126).  
Breast cancer is a heterogeneous disease, which has been classified into 
various categories based on different criteria such as histopathological type, 
grade and stage of tumors and expression of genes and proteins. Based on 
variations in gene expression patterns, breast tumors have been classified into 
five “Intrinsic” subtypes of breast cancer (claudin-low, basal-like, HER2-enriched, 
luminal A and luminal B) (127, 128). Claudin-low and basal-like breast cancers 
do not express significant levels of estrogen receptor (ER), progesterone 
receptor (PR) and HER2 and are hence called triple negative breast cancers 
(TNBCs). TNBCs have a worse prognosis than other breast cancer subtypes. 
The above mentioned molecular subtypes show crucial differences in incidence, 
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survival and response to treatment (128, 129). One of the major reasons for 
classifying breast tumors into these categories is to increase the efficacy of 
cancer treatment and to personalize therapy for each patient. Since autophagy is 
gaining importance as a potential therapeutic target, determining whether to 
therapeutically inhibit or induce autophagy for the treatment of a given tumor 
would be crucial and this could be dependent upon the subtype of breast cancer.  
In this chapter I investigated the autophagy-dependency of triple-negative 
and luminal breast cancer subtypes. I first examined the levels of autophagy in a 
panel of cell lines consisting of both basal-B and luminal subtypes, and then 
evaluated the effect of inhibiting autophagy in representative cell lines of each 
subtype. My results suggest a greater dependency of TNBCs on autophagy than 
luminal breast cancers.  
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Results 
Triple-negative breast cancer cell lines have higher levels of basal 
autophagy than luminal breast cancer cell lines 
To determine basal autophagy levels in breast carcinoma cell lines, basal, 
triple-negative (MDA-MB-231, SUM149) and luminal (MCF7 and T47D) cells 
(Table 3.1) were compared. A common method of measuring autophagy is to 
assess the lipidation of the autophagy reporter protein LC3-I to LC3-II. Lipidation 
(conjugation of phosphatidylethanolamine to LC3-I) increases the electrophoretic 
mobility of the protein as shown in Figure 3.1. To measure basal autophagy, all 
cell lines were grown in nutrient-replete conditions for 24 hours before harvesting. 
Comparison of LC3-II levels indicate increased processing of LC3-I in the 
metastatic, TNBC subtypes as compared to the non-metastatic, luminal cells. 
The increase in levels of LC3-II in the triple-negative breast cancer cell 
lines could be due to decreased fusion between the autophagosome and the 
lysosome resulting in reduced degradation of LC3-II (130). Depletion of lysosome 
associated membrane protein-1 (LAMP-1) and LAMP-2, the major components 
of the lysosomal membrane, leads to accumulation of autophagic vacuoles and 
hence LC3-II (131). Thus the levels of LAMP-1 protein in all the cell lines were 
assessed (Figure 3.1). However, no clear correlation between LC3-II and LAMP-
1 protein levels was observed. 
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Figure 3.1. Comparison of basal autophagy in breast carcinoma cell lines.  
Basal, triple-negative MDA-MB-231 and SUM149, and luminal MCF7 and T47D cells 
were lysed 24 hours after plating. Cell extracts containing equivalent amounts of total 
protein were immunoblotted with antibodies specific for LAMP-1, LC3 and actin. Images 
are from the same immunoblot that was cropped to remove lanes.  
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Accumulation of LC3-II can be due to induction of autophagy or inhibition 
of the downstream degradation pathway. Furthermore, low levels of LC3-II could 
be the result of high autophagic flux resulting in enhanced degradation of the 
protein (130). Hence to measure this dynamic process, LC3-II turnover was 
assessed in the presence of the lysosomal inhibitor chloroquine diphosphate 
(CQ) (130). Chloroquine diphosphate inhibits lysosomal acidification, thereby 
preventing degradation of autolysosomal contents including LC3-II. To compare 
autophagic flux between triple-negative and luminal cells, MDA-MB-231 and 
T47D cell lines were analyzed as representative cell lines. Cells were incubated 
for 4 and 8 hours in either nutrient replete media or in serum and amino acid-free 
Hank’s Balanced Salt Solution (HBSS) with and without 25 µM chloroquine 
diphosphate. MDA-MB-231 cells showed high levels of basal LC3-II lipidation, 
which was enhanced upon induction of autophagy by serum and amino acid 
deprivation (Figure 3.2A and B; Lanes 1 and 3). Addition of chloroquine 
diphosphate further elevated the LC3-II protein levels (compare Lane 1 with 2, 
and lane 3 with 4) indicating that increased processing of LC3-I to LC3-II was 
due to elevated autophagy and not impairment in LC3-II clearance.  
In T47D cells, LC3-II protein accumulated upon addition of chloroquine 
diphosphate to cells in nutrient replete media indicating the presence of intact low 
basal autophagy levels in the cells (Figure 3.2A and B; Lanes 5 and 6). However, 
in contrast to the MDA-MB-231 cells, upon induction of autophagy by serum and 
amino acid deprivation, the protein levels did not increase (Figure 3.2A and B;  
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Figure 3.2. Comparison of autophagic flux between MDA-MB-231 and T47D cells.  
MDA-MB-231 and T47D cells were incubated for 4 hours (A) or 8 hours (B) in either 
complete or serum and amino acid-free media with or without 25 µM chloroquine 
diphosphate. Cell extracts containing equivalent amounts of total protein were 
immunoblotted with antibodies specific for LC3 and actin or tubulin. FBS, fetal bovine 
serum; AA, amino acids. 
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Lanes 7). Moreover, addition of chloroquine diphosphate did not enhance the 
LC3-II levels of starved cells, indicating that T47D cells do not upregulate 
autophagy to counteract starvation-induced stress (Figure 3.2A and B; Lanes 8). 
Thus, triple-negative MDA-MB-231 cells have higher autophagic flux than luminal 
T47D cells and further elevate the flux under starvation conditions. 
Transformed cells undergo metabolic reprogramming known as the 
“Warburg effect” during which aerobic glycolysis is upregulated (134). This leads 
to increased glucose uptake and lactate production. Autophagy has been shown 
to facilitate increased glycolysis in Ras transformed cells and inhibition of 
autophagy in these cells reduces glucose uptake and metabolism (135). MDA-
MB-231 cells harbor a K-Ras mutation (Table 3.1).  Hence, in order to determine 
whether autophagic flux differences observed between MDA-MB-231 and T47D 
cells were due to differences in glycolysis, glucose uptake and lactate production 
were compared.  Interestingly, MDA-MB-231 and T47D cells had similar levels of 
lactate production (Figure 3.3A) and glucose uptake (Figure 3.3B). These data 
implicate that the observed differences in autophagy were not due to differences 
in glycolytic metabolism. 
Triple-negative MDA-MB-231 breast carcinoma cells are more sensitive to 
autophagy inhibition than luminal T47D cells 
In order to determine the functional contribution of autophagy in the two 
cell lines, two key characteristics of tumor cells were measured – anchorage-  
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Figure 3.3. Comparison of aerobic glycolysis in breast carcinoma cell lines. 
MDA-MB-231, SUM149, MCF7 and T47D cells were assayed for lactate production (A) 
and glucose uptake (B). The data are expressed as the rate of glucose depletion from or 
lactate production into the culture medium (mM/mg of total protein/hour) relative to MDA-
MB-231 cells. The data shown represent the mean of three independent experiments 
performed in triplicate. *, p < 0.05. 
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dependent and anchorage-independent growth. To assess the effect of inhibiting 
autophagy on the growth the two cell lines, MDA-MB-231 and T47D cells were 
incubated with different concentrations of the lysosomotropic agent chloroquine 
diphosphate for three days. Both of the cell lines showed a decrease in cell 
number upon inhibition of autophagy with the highest concentration (25µM) of the 
inhibitor. A similar 30% - 40% decrease in growth of the MDA-MB-231 cells was 
observed with both 6.25µM and 25µM of chloroquine diphosphate (Figure 3.4A 
and B). However, no significant difference in cell number was observed when 
T47D cells were treated with the lowest concentration (6.25µM) of the inhibitor 
(Figure 3.4C and D). Thus, the growth of MDA-MB-231 cells with higher 
autophagy flux was more sensitive to inhibition of autophagy. 
Anchorage-independent growth is one of the hallmarks of transformed 
cells. It gives tumor cells the potential to disseminate and metastasize (136). The 
dependence of the metastatic MDA-MB-231 and non-metastatic T47D cells on 
autophagy for anchorage-independent growth was evaluated. The cells were 
grown in soft agar in the presence of increasing concentrations of chloroquine 
diphosphate. Although T47D cells showed a 40% - 60% decrease in the number 
and size of soft agar colonies upon treatment with 25µM of chloroquine 
diphosphate, no significant decrease in colony formation was observed with 
12.5µM of the inhibitor (Figure 3.5A and C). In contrast, MDA-MB-231 cells 
formed almost no colonies in the presence of both high (25µM) and low (12.5µM) 
concentrations of the inhibitor.  Moreover, the few colonies that formed were 
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Figure 3.4. The anchorage-dependent growth of MDA-MB-231 cells is more 
sensitive to autophagy inhibition when compared with T47D cells. 
MDA-MB-231 (A, B) and T47D (C, D) cells were treated with 6.25 µM or 25 µM 
chloroquine diphosphate and growth was determined on each day by MTT assay. Data 
are expressed as absorbance (optical density) relative to Day 0 (A, C) and as percent 
proliferation normalized to untreated cells. The data shown represent the mean of three 
independent experiments performed in quadruplicate. *, p < 0.05; **, p < 0.005; ***, p < 
0.0005 
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Figure 3.5. The anchorage-independent growth of MDA-MB-231 cells is more 
sensitive to autophagy inhibition when compared with T47D cells. 
MDA-MB-231 and T47D cells were grown in soft agar and treated with or without 12.5 
µM or 25 µM chloroquine diphosphate. (A) Representative images of the cells treated 
with the inhibitor. (B, C) The number of colonies formed was quantified and are 
represented relative to untreated cells. The data shown represent the mean of three 
independent experiments performed in duplicate. *, p < 0.05; **, p < 0.005; ***, p < 
0.0005. 
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reduced in size  (less than 5000 square pixels in area) (Figure 3.5A and B). Thus, 
these data suggest that the two cell lines have differential sensitivities to 
autophagy inhibition, with the triple-negative, metastatic MDA-MB-231 cells being 
more dependent on autophagy for both anchorage-dependent and anchorage 
independent growth than the luminal, non-metastatic T47D cells.  
Genetic disruption of autophagy inhibits the anchorage-independent 
growth of MDA-MB-231 cells  
 The contribution of autophagy in the previous experiments was 
determined by using the pharmacological inhibitor chloroquine diphosphate. 
However, since this anti-malarial agent inhibits lysosomal acidification, it can also 
have autophagy-independent effects (137). Hence, to directly inhibit autophagy in 
the MDA-MB-231 cells, a genetic approach was taken. The expression of two 
critical autophagy-regulators, ATG5 and BECN1, was suppressed with targeted 
lentiviral shRNA. Two stable cell lines expressing independent shRNA were 
generated for each of the autophagy proteins. From here on these cell lines will 
be referred to as shATG5 (#1), shATG5 (#2), shBECN1 (#1) and shBECN1 (#2) 
cells. Autophagic flux was monitored in these autophagy-deficient cells by 
incubating them for 4 hours in either nutrient replete media or in HBSS with and 
without 25 µM chloroquine diphosphate. Depletion of ATG5 using shATG5 (#1) 
and to a lesser extent shATG5 (#2) decreased the autophagic flux. Induction of 
autophagy by serum starvation did not elevate LC3-II protein levels in these cell 
54
 
 
Figure 3.6. Autophagic flux in cells with suppression of ATG5 or Beclin 1 
expression. 
(A) MDA-MB-231 cells expressing shGFP and shATG5 (#1) and (#2) were incubated for 
4 hours in either complete or serum and amino acid-free media with or without 25 µM 
chloroquine diphosphate. Cell extracts containing equivalent amounts of total protein 
were immunoblotted with antibodies specific for LC3, ATG5 and tubulin. shGFP and 
shATG (#2) images are from the same immunoblot that was cropped to remove lanes. 
(B) MDA-MB-231 cells expressing shGFP, shBECN1 (#1) and (#2) were incubated for 4 
hours in either complete or serum and amino acid-free media with or without 25 µM 
chloroquine diphosphate. Cell extracts containing equivalent amounts of total protein 
were immunoblotted with antibodies specific for LC3, Beclin 1 and tubulin. FBS, fetal 
bovine serum; AA, amino acids. 
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lines (Figure 3.6A). In contrast to the results with shATG5, lipidation of LC3-I to 
LC3-II was not inhibited in the BECN1 depleted cells (Figure 3.6B).  
To examine the contribution of autophagy to the anchorage-independent 
growth of MDA-MB-231 cells, shATG5 (#1) and (#2) and shBECN1 (#1) and (#2) 
cells were grown in soft agar to assess colony formation. Suppression of both 
ATG5 and Beclin 1 reduced the colony forming ability of MDA-MB-231 cells, 
similar to the results obtained with chemical inhibition of autophagy. A 40% - 50% 
decrease in the total number of colonies greater than 3000 square pixels was 
observed upon suppression of shATG5 (Figure 3.7). shBECN1 cells also showed 
a significant decrease (78% - 97%) in anchorage-independent growth. Overall 
the data indicate that autophagy facilitates anchorage-independent growth in 
MDA-MB-231 cells, which show sensitivity to both genetic and pharmacological 
inhibition of this degradative process. Of note, shBECN1 cells showed a more 
significant reduction in anchorage-independent growth when compared with 
shATG5 cells, suggesting that Beclin 1 may regulate additional pathways that are 
important for soft agar growth.  
Suppression of ATG5 but not Beclin 1 inhibits aerobic glycolysis  
Ras transformed cells have been shown to require autophagy to maintain 
their high glycolytic rates (135).  Therefore, I next examined the glycolytic 
capacity of shATG5 and shBECN1 cells.  Consistent with previous reports,  
ATG5 depletion reduced glucose metabolism in MDA-MB-231 cells.  However,  
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Figure 3.7. Autophagy facilitates anchorage-independent growth in MDA-MB-231 
cells. 
MDA-MB-231 expressing shGFP, shATG5 (#1 and #2) or shBECN1 (#1 and #2) were 
grown in soft agar. (A) Representative images of the cells. (B) The number of colonies 
formed was quantified and are represented relative to shGFP cells. The data shown 
represent the mean of two independent experiments performed in duplicate. All values 
are significant compared to shGFP except those marked as n.s. n.s, not significant. 
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suppression of Beclin 1 resulted in no difference in the aerobic glycolysis of the 
cells when compared to control shGFP cells. The differences between the 
shATG5 and shBECN1 cells implicate additional non-autophagic roles for Beclin 
1, which enable Beclin 1-depleted cells to maintain their enhanced aerobic 
glycolytic rates. 
  
58
 
 
 
 
 
Figure 3.8. Suppression of ATG5, but not Beclin 1, expression inhibits glycolysis 
in MDA-MB-231 cells. 
MDA-MB-231 cells expressing shGFP, shATG5 (#1 and #2) or shBECN1 (#1 and #2) 
were assayed for lactate production (A) and glucose uptake (B). The data are expressed 
as the rate of glucose depletion from or lactate production into the culture medium 
(mM/mg of total protein/hour) relative to MDA-MB-231 shGFP cells. The data shown 
represent the mean of three independent experiments performed in triplicate. *, p < 0.05. 
59
Discussion 
The study performed in this chapter indicates a tumor-promoting role for 
autophagy in a triple-negative, metastatic breast carcinoma cell line. I found that 
these cells had higher levels of basal and induced autophagy and were more 
sensitive to chemical inhibition of this degradative process when compared with 
the luminal breast cancer cells. Both anchorage-dependent and anchorage-
independent growth of the triple-negative breast carcinoma cells were impeded 
to a greater extent upon inhibition of autophagy than observed for the luminal 
cells. Furthermore, I also demonstrate that RNAi-mediated suppression of the 
autophagy-regulating proteins ATG5 and Beclin 1 reduced anchorage-
independent growth, with the decrease in soft agar colony formation being more 
significant upon Beclin 1 depletion. In addition, suppression of ATG5, but not 
Beclin 1, decreased glycolysis in the triple-negative MDA-MB-231 cells. My data 
suggest that Beclin 1 may have additional autophagy-independent functions that 
rescue glycolysis. 
This study, as well as preliminary data (not shown), indicate that triple-
negative breast carcinoma cell lines have higher levels of autophagy than luminal 
breast carcinoma cell lines. Moreover, starvation did not induce autophagy in 
luminal cells. MDA-MB-231 cells have a higher rate of proliferation than T47D 
cells and highly proliferating tumor cells are heavily dependent on glycolysis for 
supplying energy and biosynthetic intermediates (the Warburg effect). Activation 
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of several oncogenes including Ras has been shown to elevate aerobic 
glycolysis. The Ras oncogene impairs production of acetyl-CoA that feeds into 
the mitochondrial tricarboxylic acid (TCA) cycle, thereby decreasing 
mitochondrial respiration and increasing the production of lactic acid, a byproduct 
of glycolysis (90). Moreover, a study performed by Lock et. al. showed that 
autophagy facilitates increased glycolysis in Ras transformed cells and 
impairment of autophagy reduces their glycolytic capacity (135). Comparison of 
the amount of glucose taken up and lactate produced by MDA-MB-231 and T47D 
with high and low autophagic flux respectively, showed no difference in the level 
of glycolysis between the two cell lines.  Since MDA-MB-231 cells have an 
activating K-Ras mutation, increased levels of autophagy may be required to 
support their glycolytic rates.  
During the course of this work studies by Guo et. al., Lock et. al., Kim et. 
al. and Yang et. al. were published, which showed that Ras driven tumor cells 
upregulate autophagy and are “addicted” to this degradative process  (110, 125, 
135, 138). My studies suggest that differences in autophagy in the triple-negative 
and luminal cell lines were not due to differences in the glycolytic capacities of 
the MDA-MB-231 cells and the T47D cells. Increased glycolytic rates are 
accompanied by a decrease in mitochondrial oxidative phosphorylation. 
Nonetheless, functional mitochondrial metabolism and its generation of reactive 
oxygen species (ROS) to activate signaling pathways is required for K-Ras-
mediated proliferation and tumorigenesis (139). Apart from maintaining the 
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quality of mitochondria by eliminating damaged organelles by mitophagy, 
autophagy can also support oxidative mitochondrial metabolism by providing 
biosynthetic intermediates to the TCA cycle. Degradation of protein and lipids by 
autophagy generates metabolites that can be used by the TCA cycle. In support 
of this, inhibition of autophagy in pancreatic ductal adenocarcinoma (PDAC) cells 
with activated Ras led to a decrease in TCA cycle metabolites and ATP (110, 
125). These studies indicate that one of the reasons for elevated basal 
autophagy that we observed in the triple-negative MDA-MB-231 cells may be to 
maintain functional mitochondrial metabolism and ATP levels in rapidly dividing 
cells. 
Luminal T47D breast cancer cells exhibited low levels of autophagy and 
low sensitivity to inhibition of anchorage-independent growth. T47D cells, as well 
as MCF7 cells, have gain-of-function mutations in the PIK3CA gene, which 
encodes for the p110α catalytic subunit of class I PI3K (129, 140). These 
mutations lead to increased activation of PI3K and its downstream pathway. 
Elevated levels of AKT phosphorylation in T47D cells result in activation of the 
negative regulator of autophagy, mTORC1 (141). This inhibition could explain the 
lower autophagic flux observed in the luminal T47D cell line. These less 
aggressive cells could also resort to an alternate mode of maintaining metabolic 
fitness such as microautophagy and chaperone mediated autophagy (CMA). In 
microautophagy, proteins and organelles are directly engulfed into the lysosome 
(142). On the other hand during CMA, chaperone proteins recognize and bind 
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damaged and oxidized cytosolic proteins. These proteins are subsequently 
delivered into the lysosome after binding with the lysosomal protein LAMP-2A 
(36). Upregulation of CMA in various cancer cell lines including MCF7 cells has 
been reported (143). Additionally, elevated expression of LAMP-2A has also 
been observed in human breast tumor samples. Moreover, LAMP-2A over 
expression in T47D and MCF7 cells provided protection against oxidative 
damage (144). In my studies assessment of LAMP-1 protein levels indicated high 
lysosomal content in T47D but not MCF7 cells. The expression of LAMP-2A 
should be assessed in these cells to determine the involvement of CMA. 
Luminal T47D cells were less sensitive to inhibition of lysosomal 
degradation with chloroquine diphosphate than triple-negative MDA-MB-231 cells. 
Under stress conditions such as contact-independent growth or uncontrolled 
proliferation, luminal cells could decrease protein synthesis as an alternative 
mechanism to overcome bioenergetic deficiencies. In support of this possibility, 
total LC3 levels were reduced in T47D cells upon serum starvation. These cells 
could also utilize the ubiquitin proteasome system to accelerate degradation of 
unwanted and damaged proteins. Further studies are required to determine how 
these cells maintain homeostasis when autophagy is inhibited. 
As mentioned earlier, autophagy supports aerobic glycolysis in Ras 
mutant cells (135). Indeed, inhibition of ATG5 resulted in decreased glycolysis in 
MDA-MB-231 cells that have an activating Ras mutation. However, depletion of 
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Beclin 1 showed no effect on glucose metabolism. One explanation for this 
difference could be an increase in growth factor receptor signaling. Beclin 1 has 
been reported to regulate receptor degradation, with suppression of Beclin 1 
protein levels decreasing EGFR degradation (19). Inhibition or delay in receptor 
degradation could result in increased growth factor receptor signaling that can 
regulate nutrient uptake by activating pathways such as the PI3K/AKT pathway. 
Increased signaling through this pathway in turn would enhance glycolysis in 
cancer cells by regulating translocation of the glucose transporter GLUT1 to the 
cell surface and activation of hexokinase and phosphofructokinase enzymes 
involved in glycolysis (145). Therefore, the decrease in glycolysis due to 
inhibition of autophagy could be compensated for by increased growth factor 
receptor signaling, thereby maintaining glycolytic rates in Beclin 1-suppresssed 
MDA-MB-231 cells. Thus, my data implicates potential autophagy-independent 
functions of Beclin 1 that can regulate glycolysis in these cells.  
My study and others demonstrate a dependency of triple-negative breast 
carcinoma cells on autophagy, suggesting that this subtype of breast cancer may 
be a good candidate for treatment with autophagy inhibitors (129). In addition to 
MDA-MB-231 cells, my preliminary experiments showed a similar increase in 
autophagic flux in additional triple-negative breast cancer cells lines. My findings 
are consistent with the recently published work by Maycotte et.al. Similar to my 
observations they found an increased sensitivity of triple-negative breast 
carcinoma cell lines to autophagy inhibition when compared with luminal and 
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non-tumorigenic cells (129). Thus, the efficacy of treatment of cancer by 
inhibiting autophagy is context-dependent, and for breast cancer it may depend 
upon the molecular subtype of the tumor. 
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Introduction 
Beclin 1 is the mammalian homolog of the yeast Atg6/Vacuolar protein 
sorting 30 (Vps30) protein that plays an essential role in autophagy and vacuolar 
protein sorting (1, 2). Beclin 1 is required for normal mammalian development 
and it has been shown to play a critical role in pathogenesis, including cancer (35, 
94). Mice heterozygous for Beclin 1 expression (Becn1+/-) have an increased 
incidence of lymphoma and carcinomas of the lung and liver, and these mice 
also show preneoplastic changes in the mammary gland tissue as they age (35, 
94). Additionally, heterozygous loss of Beclin 1 promotes mammary 
tumorigenesis in response to parity and WNT1 activation (146). These studies 
support a role for Beclin 1 as a haploinsufficient tumor suppressor gene in a 
context-dependent manner. In many human tumors Beclin 1 mRNA and protein 
expression are decreased, the result of both monoallelic loss of the BECN1 gene 
and aberrant DNA methylation that suppresses gene expression (96). Mutation of 
BECN1 has not been detected in tumors (95). Reduced Beclin 1 protein 
expression is associated with poor prognosis in several cancer types, including 
breast (97, 98). 
The investigation of Beclin 1 function in cancer has focused primarily on 
its role in regulating autophagy. Becn1+/- mice show evidence of decreased 
autophagy and immortalized Becn1+/- mouse mammary epithelial cells exhibit a 
ROS-mediated DNA damage response that is attributed to the accumulation of 
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damaged mitochondria when autophagy is impaired. This increase in DNA 
damage has been implicated in transformation (109). However, additional 
membrane trafficking functions of Beclin 1 play significant roles in tissue 
homeostasis and their dysregulation could contribute to tumor cell biology.  
Beclin 1 regulates membrane trafficking through its interaction with Vps34/Class 
III PhosphatidylinositoI-3 Kinase (PI3KC3), a lipid kinase that phosphorylates PI 
to generate the lipid second messenger PI-3 phosphate (PI3P) (147, 148). PI3P 
mediates the recruitment of proteins containing FYVE (Fab1p, YOTB, Vac1p, 
EEA1) and PX (Phox homology) domains to intracellular membranes to facilitate 
vesicular fusion and sorting events (149-151). Beclin 1 regulates distinct 
membrane trafficking pathways through mutually exclusive recruitment of 
additional binding partners. For example, Beclin 1 interacts with 
Atg14/ATG14L/Barkor (Complex I) to regulate autophagy initiation and 
Vps38/UVRAG (Complex II) to regulate vacuolar protein sorting, cytokinesis and 
receptor degradation (12, 13).   
In the previous chapter, I demonstrated that Beclin 1 has autophagy-
independent features that are likely to contribute to its role in cancer. These 
studies revealed a potential role for the regulation of growth factor receptor. 
Given the importance of growth factor receptor signaling in normal cell function 
and the consequences of its dysregulation in cancer, I assessed the role of 
Beclin 1 in regulating receptor endocytic trafficking and signaling, and sought to 
determine the mechanism involved. The data I report here reveal a novel role for 
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Beclin 1 in regulating growth factor receptor signaling that involves the control of 
early endosome maturation. My findings have important implications for 
understanding how Beclin 1 loss contributes to cancer.  
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Results 
Beclin 1 regulates growth factor receptor signaling 
Intracellular signaling by growth factor receptors is controlled by trafficking 
through compartments of the endocytic pathway. Factors that regulate receptor 
movement from the early endosome compartment to either the late 
endosome/lysosome compartment for signal termination and degradation or the 
recycling endosome compartment for restoration of surface expression control 
the strength and duration of signal transduction. To investigate a role for Beclin 1 
in the regulation of growth factor receptor signaling, I examined the link between 
Beclin 1 and two growth factor receptors that have been implicated in breast 
cancer, the insulin-like growth factor-1 (IGF-1) receptor and the epidermal growth 
factor (EGF) receptor. The IGF-1R is frequently overexpressed in breast tumors 
and its activation correlates with poor prognosis (152, 153), whereas the EGFR is 
frequently elevated in expression and activation in the triple negative breast 
cancer (TNBC) subtype (154).   
MDA-MB-231 cells (TNBC subtype), MCF7 cells (luminal breast cancer 
subtype) and MCF10A cells (immortalized mammary epithelial cells) were stably 
infected with shRNAs targeting BECN1 (shBECN1) or GFP (shGFP). IGF-1R 
protein levels were monitored in Beclin 1-depleted cells growing in nutrient-rich 
media. Suppression of Beclin 1 expression increased IGF-1R protein levels in all 
three cell lines (Figure 4.1A). Conversely,  stable over-expression of flag-tagged 
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Figure 4.1. Beclin 1 depletion increases IGF-1R protein levels. 
(A,B) Cell extracts from MCF10A, MCF7 and MDA-MB-231 cells expressing shGFP or 
shBECN1 (A) or MCF7 cells expressing Flag-Beclin 1 (B) were immunoblotted with the 
indicated antibodies. (C) IGF-1R and BECN1 mRNA levels were determined by qRT-
PCR. The data shown represent the mean of three independent experiments. n.s, not 
significant. 
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Beclin 1 in MCF7 cells, which express the highest levels of IGF-1R, reduced IGF-
1R expression (Figure 4.1B). Importantly, no significant change in mRNA 
expression was detected, indicating that Beclin 1 regulates the expression of 
IGF-1R at the level of protein expression and/or degradation (Figure 4.1C). 
To investigate the impact of Beclin 1 on growth factor receptor signaling, 
phosphorylation of key downstream signaling effectors of the IGF-1R and EGFR, 
the serine/threonine kinases AKT and ERK1/2, was assessed in response to a 
time course stimulation with either IGF-1 (Figure 4.2-4.4) or EGF (Figure 4.5). 
AKT and ERK1/2 were phosphorylated in a transient manner in response to IGF-
1 and EGF stimulation in control shGFP cells. In contrast, phosphorylation levels 
increased and were sustained at later time points in the shBECN1 cells 
(quantified in Figures 4.2-4.5). Although similar trends were observed for both 
AKT and ERK in response to both ligands, the impact on AKT phosphorylation 
was significant downstream of the IGF-1R and ERK1/2 phosphorylation 
downstream of the EGFR. These data reflect the dominant signaling pathways 
that are activated by each of these receptors. In addition, the IGF-1-dependent 
increase in AKT phosphorylation upon Beclin 1 loss was greater for T308 than for 
S473. Ectopic expression of Beclin 1 significantly decreased IGF-1-dependent 
AKT activation in the parental MDA-MB-231 cells (Figure 4.6), whereas the 
elevated signaling observed in the shBECN1 MDA-MB-231 cells decreased upon 
rescue of Beclin 1 expression (Figure 4.7). Taken together my data reveal that 
Beclin 1 negatively regulates the intensity and duration of growth factor receptor
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Figure 4.2. Beclin 1 regulates IGF-1-dependent signaling in MDA-MB-231 cells. 
(A) MDA-MB-231 cells expressing shGFP, shBECN1 (#1) or shBECN1 (#2) were serum-
starved overnight and then stimulated with IGF-1 (100ng/ml) for the indicated time 
periods. Cell extracts were immunoblotted with the indicated antibodies. Phospho-
AKT(S473) (B) and phospho-AKT(T308) (C) levels were quantified by densitometry. The 
data shown represent the mean of three (C) or four (B) independent experiments. *, p < 
0.05 ; **, p < 0.005; ***,  p < 0.0005. 
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Figure 4.3. Beclin 1 regulates IGF-1-dependent signaling in MCF7 cells. 
(A) MCF7 cells expressing shGFP, shBECN1 (#1) or shBECN1 (#2) were serum-starved 
overnight and then stimulated with IGF-1 (100ng/ml) for the indicated time periods. Cell 
extracts were immunoblotted with the indicated antibodies. Phospho-AKT(T308) levels 
were quantified by densitometry. The data shown represent the mean of three 
independent experiments. *, p < 0.05. 
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Figure 4.4. Beclin 1 regulates IGF-1-dependent signaling in MCF10A cells. 
(A) MCF10A cells expressing shGFP, shBECN1 (#1) or shBECN1 (#2) were serum-
starved overnight and then stimulated with IGF-1 (100ng/ml) for the indicated time 
periods. Cell extracts were immunoblotted with the indicated antibodies. Phospho-
AKT(T308) levels were quantified by densitometry. The data shown represent the mean 
of three independent experiments. *, p < 0.05. 
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Figure 4.5. Beclin 1 regulates EGF-dependent signaling. 
(A) MDA-MB-231 cells expressing shGFP, shBECN1 (#1) or shBECN1 (#2) were serum-
starved overnight and then stimulated with EGF (50ng/ml) for the indicated time periods. 
Cell extracts were immunoblotted with the indicated antibodies. Phospho-AKT(S473) (B) 
and phospho-MAPK (T202/Y204) (C) levels were quantified by densitometry. The data 
shown represent the mean of three independent experiments. *, p < 0.05; **, p < 0.005. 
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Figure 4.6. Ectopic expression of Beclin 1 decreases growth factor-dependent 
signaling. 
MDA-MB-231 cells transiently expressing Flag-Beclin 1 were stimulated with IGF-1 
(100ng/ml) for the indicated time periods. Cell extracts were immunoblotted with the 
indicated antibodies. Phospho-AKT(S473) and Phospho-AKT(T308) levels were 
quantified by densitometry. The data shown represent the mean of three independent 
experiments. *, p < 0.05; **, p < 0.005. 
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Figure 4.7. Rescue of Beclin 1 expression restores growth factor-dependent 
signaling to control levels. 
MDA-MB-231 cells expressing shGFP, shBECN1 or shBECN1 and Flag-Beclin 1 were 
stimulated with IGF-1 (100ng/ml) for the indicated time periods. Cell extracts were 
immunoblotted with the indicated antibodies. Phospho-AKT(S473) and Phospho-
AKT(T308) levels were quantified by densitometry. The data shown represent the mean 
of three independent experiments. *, p < 0.05. 
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signaling. 
Beclin 1 in receptor degradation and signaling  
My observation that suppression of Beclin 1 increased IGF-1R protein 
levels without a concomitant increase in mRNA levels (Figure 4.1) suggested a 
role for Beclin 1 in controlling receptor degradation. In mammalian systems, there 
have been conflicting reports regarding the role of Beclin 1 in the regulation of 
degradative endocytic trafficking. One study concluded that Beclin 1 does not 
participate in the regulation of EGFR endocytic trafficking and is only required for 
autophagic membrane trafficking (84), while a separate study identified a role for 
Beclin 1 in regulating the rate of EGFR degradation (19). To investigate this 
mechanism of action for Beclin 1, the rate of EGFR and IGF-1R degradation and 
signaling after stimulation with their cognate ligands was examined. Serum 
starved cells treated with cycloheximide to prevent de novo protein expression, 
were stimulated with either EGF or IGF-1 over a 6 hour period followed by 
protein analysis. Consistent with the latter study (19) a reduction in the rate of 
EGFR (Figure 4.8A and B) degradation was observed. However, IGF-1R was 
found to be more stable over the time course analyzed and only a slight 
decrease in its degradation during the early time points was detected (Figure 
4.9A and B). Importantly, phosphorylation of AKT and MAPK remained elevated 
in the shBECN1 cells over this extended time course (Figure 4.8A, C, D and 4.9A, 
C). 
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Figure 4.8. Regulation of EGFR degradation and signaling by Beclin 1.  
MDA-MB-231 cells expressing shGFP or shBECN1 were pre-incubated with 
cycloheximide (50µg/ml) for 1hr and then stimulated with EGF (50ng/ml) in the presence 
of cycloheximide for 0-6 hours. Cell extracts were immunoblotted with the indicated 
antibodies. EGFR protein (B), phospho-AKT(S473) (C) and phospho-MAPK (T202/Y204) 
(D) levels were quantified by densitometry. The data shown represent the mean of two 
independent experiments. *, p < 0.05.  
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Figure 4.9. Regulation of IGF-1R degradation and signaling by Beclin 1.  
MDA-MB-231 cells expressing shGFP or shBECN1 were pre-incubated with 
cycloheximide (50µg/ml) for 1hr and then stimulated with IGF-1 (100ng/ml) in the 
presence of cycloheximide for 0-6 hours. Cell extracts were immunoblotted with the 
indicated antibodies and IGF-1R protein (B) and phospho-AKT(S473) (C) levels were 
quantified by densitometry. The data shown represent the mean of two independent 
experiments. *, p < 0.05.  
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To determine if the effect of Beclin 1 on growth factor receptor degradation, 
AKT and MAPK activation involved its autophagic function, similar assays were 
performed after suppression of ATG5, an essential autophagy gene that is 
required for the formation and maturation of autophagosomes (155). Suppression 
of ATG5 significantly impaired autophagy in response to serum deprivation, as 
monitored by LC3 II levels (Figure 3.6A). In contrast to the delayed degradation 
observed in the shBECN1 cells, the rate of EGFR degradation upon suppression 
of ATG5 expression was similar to the control cells (Figure 4.10A and B). 
Furthermore, AKT and MAPK phosphorylation were neither elevated nor 
sustained in the absence of ATG5 (Figure 4.10A, C and D). In addition, chemical 
inhibition of autophagy with the lysosomotropic agent chloroquine diphosphate 
also did not increase AKT phosphorylation at either site (Figure 4.11). Inhibition 
of autophagy was confirmed by assessing the levels of LC3-II which accumulated 
in cells treated with the inhibitor. Taken together, the data indicate that Beclin 1 
regulates growth factor-stimulated AKT and MAPK activation through an 
autophagy-independent mechanism. 
Beclin 1 regulates growth factor receptor-dependent PI3KC3 activation and 
endosomal maturation 
Growth factor receptor signaling initiates at the cell surface and continues 
upon receptor internalization into early endosomes (156). To investigate further 
how Beclin 1 regulates signaling, receptor internalization was prevented using 
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Figure 4.10. Regulation of receptor degradation and signaling by Beclin 1 is 
autophagy-independent.  
MDA-MB-231 cells expressing shGFP or shATG5 were pre-incubated with 
cycloheximide (50µg/ml) for 1hr and then stimulated with EGF (50ng/ml) in the presence 
of cycloheximide for 0-6 hours. Cell extracts were immunoblotted with the indicated 
antibodies. EGFR protein (B), phospho-AKT(S473) (C) and phospho-MAPK(T202/Y204) 
(D) levels were quantified by densitometry. The data shown represent the mean of two 
independent experiments. *, p < 0.05. 
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Figure 4.11. Chemical inhibition of autophagy does not enhance AKT activation. 
MDA-MB-231 cells were treated with 30 µM Chloroquine diphosphate for 4 hours. Cell 
extracts were immunoblotted with the indicated antibodies. Accumulation of the lower 
migrating, lipidated form of LC3B I, LC3B II, indicates inhibition of autophagy. 
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the clathrin inhibitor chlorpromazine (157). IGF-1-dependent activation of AKT 
was markedly diminished, but equivalent, in both the shGFP and shBECN1 cells 
in the presence of the clathrin inhibitor (Figure 4.12). This result suggested that 
Beclin 1 regulates growth factor receptor signaling post-internalization by 
controlling the trafficking of receptors from an early endosomal compartment that 
retains active signaling capacity (158). Recent studies have revealed that early 
endosomes, which are positive for the GTPase Rab5, are comprised of 
functionally distinct subpopulations of vesicles that differ in binding partners and 
signaling potential (159, 160). One such subpopulation is characterized by the 
presence of the adaptor protein APPL1, which binds both Rab5 and AKT and can 
regulate both AKT and MAPK activation (161-163). APPL1 also interacts with 
growth factor receptors including the EGFR (164) and insulin receptor (165).  
APPL1-positive (APPL1+) endosomes lack the lipid PI3P. When they mature 
from PI3P negative (PI3P-) endosomes to PI3P+ endosomes, APPL1 is 
displaced by FYVE-domain containing proteins, such as EEA1 and rabenosyn5, 
which bind competitively to both Rab5 and PI3P (160). In support of a role for 
Beclin 1 in regulating early endosome trafficking, knockout of Beclin 1 (ATG6) in 
the Drosophila fat body interferes with the movement of Rab5-positive vesicles 
from the plasma membrane to the perinuclear compartment (83). 
To determine if suppression of Beclin 1 inhibits the maturation of PI3P- 
/APPL+ endosomes, thereby sustaining the activation of AKT and MAPK, shGFP  
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Figure 4.12. Beclin1 regulates growth factor signaling in early endosomes.  
MDA-MB-231 cells expressing shGFP or shBECN1 were stimulated with IGF-1 
(100ng/ml) for the indicated time periods in the presence or absence of the clathrin 
inhibitor chlorpromazine (10 µg/ml). Cells treated with the inhibitor were also pre-treated 
for 1 hour with Chlorpromazine. Cell extracts were immunoblotted with the indicated 
antibodies. (B) Phospho-AKT(T308) levels were quantified by densitometry. The data 
shown represent the mean of four independent experiments. *, p < 0.05.  
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and shBECN1 cells were stained with APPL1-specific antibodies to evaluate the 
presence of APPL1+ endosomes. Images were captured using a confocal 
microscope and evaluated by counting the number of stained puncta in each cell. 
APPL1+ endosomes were more abundant and persisted over the time course of 
IGF-1 stimulation in the shBECN1 cells, compared with the shGFP cells (Figure 
4.13A and B). In contrast, the number of APPL1+ endosomes increased 
modestly only at the very earliest time point of stimulation in shATG5 cells when 
compared to control shGFP cells (Figure 4.13A and B). Suppression of ATG5 
significantly impaired autophagy in response to serum deprivation, as monitored 
by LC3 II levels (Figure 3.6A), whereas suppression of BECN1 resulted in only a 
modest reduction in LC3 II conversion (Figure 3.6B). The different results 
observed with Beclin 1 and ATG5 loss further supports our previous data and 
suggests that the regulation of early endosome trafficking involves Beclin 1 
functions that are not exclusively related to its role in autophagy. Of note, 
suppression of APPL1 expression only modestly inhibited IGF-1-dependent 
signaling to AKT, indicating that it may contribute, but is not required for, 
activation of this signaling pathway (data not shown). 
To investigate the role of Beclin 1 in early endosome receptor trafficking 
further, I quantified the residency time of growth factor receptors in APPL1+ 
endosomes using fluorophore-conjugated EGF to follow the EGFR in real-time 
using Total Internal Reflection Fluorescence (TIRF) microscopy (123). EGFR 
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Figure 4.13. Beclin1 regulates APPL1+ endosomes. 
(A) MDA-MB-231 cells expressing shGFP, shBECN1 or shATG5 were stimulated with 
IGF-1 (100ng/ml) for the time periods indicated. Cells were fixed and stained with 
antibodies that recognize APPL1 (green). Nuclei were stained with DAPI (blue). Scale 
bar, 10 µm. (B) Quantification of APPL1+ endosomes shown in (A). The data shown 
represent the mean of 23-37 independent cells. *, p < 0.05; ***, p < 0.0005. 
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trafficking has been extensively studied using this approach and a 
corresponding fluorophore-conjugated IGF-1 is not available for these analyses. 
Control and shBECN1 cells were transfected with TagRFP-T-APPL1 and 
stimulated with fluorophore-conjugated EGF to track the EGFR. Cells were 
stimulated for 8 minutes and chased for another 12 minutes (Figure 4.14A). 
Images captured were processed to remove background and generate masks 
which were used to quantify the number of EGF and APPL1+ vesicles and the 
co-localization between the two. Only cells with similar APPL1 transfection 
efficiency and EGF uptake were used for quantification (Figure 4.14C). The 
extent of EGF and APPL1 co-localization was similar between the control and 
shBECN1 cells initially, but a significant increase in co-localization occurred 
over time in the shBECN1 cells and this co-localization persisted at an elevated 
level throughout the analysis (Figure 4.14B). These results are consistent with 
Beclin 1 regulating endosome maturation and suggest the possibility that PI3P+ 
endosomes are required for down-regulation of growth factor signaling. 
If suppression of Beclin 1 decreases PI3P generation and therefore 
delays transition of PI3P- endosomes to PI3P+ endosomes, a corresponding 
decrease in receptor co-localization with the latter should occur. To monitor 
PI3P+ endosomes, a GFP-tagged FYVE domain from the endosomal protein 
SARA (EGFP-FYVE) that binds PI3P was utilized. Generation of PI3P on early 
endosomes recruits EGFP-FYVE from the cytoplasm allowing quantitation of 
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Figure 4.14. Beclin1 regulates growth factor-dependent early endosome 
maturation.  
(A) MDA-MB-231 shGFP or shBECN1 cells expressing TagRFP-T-APPL1 (red) were 
exposed to Alexa-Fluor-488-EGF (200ng/ml) (green) and imaged using TESM Optical 
System for ~20 minutes. The far left panels are representative unprocessed images with 
background removed, while the remaining panels are overlapped masks of images from 
the individual time points after ligand stimulation. Co-localized signals are represented in 
white. (B) Percent of APPL1 colocalized with EGF in 100x100 pixels section of each cell 
(8 sections for shGFP and 7 sections for shBECN1) plotted over the indicated time 
interval. (C) Average pixel intensity of EGF and APPL1 in cells after ligand stimulation. 
Spikes represent the wash out of EGF. The data shown represent the mean of two 
independent experiments performed in duplicate or triplicate. Scale bar, 3 µm. Spurious, 
non-specific co-localization. *, p < 0.05. 
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Figure 4.15. Beclin1 regulates growth factor-dependent transition to PI3P+ early 
endosomes.  
Figure legend on next page. 
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Figure 4.15. Beclin1 regulates growth factor-dependent transition to PI3P+ 
early endosomes.  
(A) shScrambled and shBECN1 cells expressing EGFP-FYVE (green) and TagRFP-T-
APPL1 (red) were exposed to DyLight 650 labelled EGF (200ng/ml) (blue) and imaged 
using TESM Optical System for ~20 minutes. The far left panels are representative 
unprocessed images with background removed, while the remaining panels are 
overlapped masks of images from the individual time points after ligand stimulation. Co-
localized signals are represented in colors indicated in the accompanying color wheel. 
Scale bar, 3 µm. (B) Average pixel intensity of EGF, FYVE and APPL1 in cells after 
ligand stimulation. Spikes represent the wash out of EGF. (C) Number of FYVE+ puncta 
present in the TIRF zone at each time point. (D,E) Percent of EGF colocalized with 
APPL1 (D) and FYVE (E) in each cell (n=6). Masks were used to quantitate 
colocalization. The data shown represent the mean of three independent experiments 
(n=6). Spurious, non-specific co-localization. *, p < 0.05. 
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PI3P+ endosomes. EGFP-FYVE was co-transfected with TagRFP-T-APPL1 and 
the cells were stimulated with fluorophore-conjugated EGF (Figure 4.15A). TIRF 
images captured were processed to remove background and generate masks 
toquantitate the number of endosomes and co-localization between them. Only 
cells with similar APPL1 and FYVE transfection efficiencies and EGF uptake 
were used for quantification (Figure 4.15B). As was observed in the cells 
expressing TagRFP-T-APPL1 alone, a significant increase in co-localization of 
EGF with APPL1 occurred over time in the shBECN1 cells (Figure 4.15D). In 
unstimulated cells, PI3P levels are low and EGFP-FYVE is found diffusely in the 
cytoplasm. Upon stimulation with EGF, EGFP-FYVE was recruited to endosomes 
in the TIRF zone in the control cells and their co-localization with EGF increased 
over time (Figures 4.15C and E). In contrast, EGFP-FYVE remained diffuse in 
the shBECN1 cells and very few positive endosomes were observed within the 
TIRF zone (Figures 4.15C and E). Rescue of Beclin 1 expression in the 
shBECN1 cells with TagRFP-T-BECN1, restored the presence of FYVE+ 
endosomes (Figure 4.16).  
As an additional measure of PI3P+ endosome maturation, cells 
transfected with TagRFP-T-APPL1 and stimulated with fluorophore-conjugated 
EGF were fixed after 25 mins of ligand exposure and stained with antibodies 
specific for EEA1, a marker of Rab5+/PI3P+ early endosomes (Figure 4.17A). 
Once again, a significant increase in the amount of APPL1 that co-localized with 
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Figure 4.16. Rescue of Beclin 1 expression restores PI3P+ endosomes. 
shBECN1 cells expressing either TagRFP-T or TagRFP-T-BECN1 (red) and EGFP-
FYVE (green) were stimulated with DyLight 650 labelled EGF (200ng/ml) (blue) for 10 
mins before fixation. The number of FYVE positive puncta in each cell was quantified. 
The data shown represents the mean of two experiments (n=11).  Scale bar, 3 µm. **, p 
< 0.005.  
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Figure 4.17. Beclin 1 controls the maturation of early endosomes.  
(A) Cells expressing TagRFP-T-APPL1 (red) were stimulated with Alexa-Fluor-488-EGF 
(200ng/ml) (green) for 25 mins, fixed and stained with antibodies that recognize EEA1 
(blue). Original images without background noise (left) were processed to generate 
masks (right).  Co-localized signals are represented by colors indicated in the 
accompanying color wheel. Scale bar, 3 µm. (B,C,D) Quantification of percent co-
localization between fluorophores in six independent cells. Percent of EGF colocalized 
with APPL1 (B) and EEA1 (C). Percent of APPL1 colocalized EEA1 (D). Masks were 
used to quantitate colocalization. (E) Immunoblots of cell extracts from (A). *, p < 0.05. 
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EGF was observed at this fixed time point in the shBECN1 cells (Figure 4.17B). 
A corresponding significant decrease in the co-localization of EGF with EEA1 
was also revealed, confirming a delay in the transition of Rab5+/PI3P- to 
Rab5+/PI3P+ endosomes (Figure 4.17C). Total EEA1 levels were equivalent in 
the shGFP and shBECN1 cells (Figure 4.17E). An increase in the co-
localization of APPL and EEA1 was also detected upon Beclin 1 depletion 
(Figure 4.17D). This increase in hybrid endosomes that have not fully matured 
provides additional evidence for a role for Beclin 1 in the efficient transition of 
this endosomal population. 
The increase in EGFP-FYVE+ endosomes in response to EGF 
stimulation and the absence of these endosomes in the shBECN1 cells indicate 
that Beclin 1 is required for the generation of PI3P in response to growth factor 
stimulation. To examine directly this role for Beclin 1 in the growth factor-
dependent regulation of PI3P generation, I measured total cellular PI3P lipids in 
response to growth factor stimulation using a competitive ELISA assay. 
Stimulation of shGFP cells with either IGF-1 or EGF increased PI3P levels 
significantly (Figures 4.18A and B). Importantly, PI3P levels did not increase 
upon stimulation of the shBECN1 cells with either IGF-1 or EGF, which is 
consistent with the absence of EGFP-FYVE endosomes in the imaging 
experiments. Combined, my data support the hypothesis that Beclin 1 regulates 
PI3KC3 activation in response to growth factor stimulation and contributes to 
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Figure 4.18. Beclin 1 controls PI3P levels. 
(A,B) MDA-MB-231 cells expressing either shGFP or shBECN1 were serum-starved 
overnight and then stimulated with IGF-1 (100ng/ml) (A) or EGF (50ng/ml) (B) for the 
indicated time periods. Total PI3P lipids were extracted and the levels were measured 
by ELISA assay. The data shown represents the mean of two (EGF; n=4) or three (IGF-
1; n=9) independent experiments. *, p < 0.05. 
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the dynamic changes in PI3P levels that accompany endosome maturation. 
Beclin 1 negatively regulates invasion in breast carcinoma cell lines 
AKT regulates migration and invasion in many tumor cell types, including breast 
carcinoma cells (166, 167). Therefore, I investigated whether loss of Beclin 1, 
and the resulting sustained activation of AKT, promotes migration or invasion. 
Suppression of Beclin 1 expression increased the invasion, but not migration, of 
MDA-MB-231 (Figure 4.19A) and SUM159 (Figure 4.19B) cells by two-four fold 
compared to control cells (shGFP) and restoration of Beclin 1 expression in the 
shBECN1 cells restored invasion to control levels (Figure 4.20). Importantly, 
inhibition of AKT activity using the inhibitor MK2206 suppressed the increased 
invasion of the MDA-MB-231 shBECN1 cells (Figure 4.21). The lack of an 
increase in migration in the shBECN1 cells suggests that the sustained AKT 
signaling that occurs upon loss of Beclin 1 selectively regulates pathways 
important for invasion, such as protease expression, and does not control 
general cell movement.   
Beclin 1 inversely correlates with phosphorylated AKT and ERK in human 
tumors 
 To assess the impact of Beclin 1 on AKT and ERK activation in human 
breast tumors, we used cBioPortal to analyze the correlation between Beclin 1 
expression and AKT and ERK phosphorylation in a cohort of breast cancer
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Figure 4.19. Beclin 1 regulates breast carcinoma cell invasion. 
(A) MDA-MB-231 cells expressing shGFP, shBECN1 (#1) or shBECN1 (#2) were 
assayed for their ability to migrate (collagen 1) or invade (Matrigel).  The data shown 
represent the mean of three (invasion; n = 7) and two (migration; n = 5) independent 
experiments performed in duplicate or triplicate. Inset, immunoblots showing Beclin 1 
expression in the shBECN1 cells. (B) SUM159 cells expressing shGFP or shBECN1 
were assayed for their ability to invade Matrigel. The data shown represent the mean of 
three independent experiments performed in triplicate (n = 9). Right, immunoblots 
showing Beclin 1 expression in the shBECN1 cells. Images are from the same 
immunoblot that was cropped to remove lanes. ***, p < 0.0005.  
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Figure 4.20. Rescue of Beclin 1 expression decreases enhanced invasion in Beclin 
1-depleted cells. 
MDA-MB-231 cells expressing shBECN1 or shBECN1 with restored FLAG-Beclin 1 
expression were assayed for their ability to invade Matrigel.  The data shown represent 
the mean of three independent experiments performed in triplicate. Inset, immunoblots 
showing Beclin 1 expression. *, p < 0.05; **, p < 0.005. 
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Figure 4.21. Inhibition of AKT signaling suppressed increased invasion in Beclin 
1-deficient cells. 
MDA-MB-231 cells were assayed for their ability to invade Matrigel after treatment with 
the AKT inhibitor MK2206 (0.5 µM). The data shown represent the mean of four 
independent experiments performed in duplicate or triplicate (n = 10). Inset, 
immunoblots showing phospho-AKT(S473) and (T308) upon treatment with 0.5 µM 
MK2206 for 1 hour. ***, p < 0.0005. 
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patients that had altered levels of Beclin 1 protein expression as measured by 
reverse phase protein array (RPPA) (168, 169). A statistically significant negative 
correlation between Beclin 1 and pAKT (S473; Pearson r = -0.3612) and pERK 
(T202; Pearson r = -0.3904) was observed (Figure 4.22).   
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Figure 4.22. Inverse correlation of Beclin 1 expression and AKT and ERK 
phosphorylation in human breast tumors.  
AKT and ERK phosphorylation were analyzed in a cohort of breast cancer patients that 
had altered levels of Beclin 1 protein expression using cBioPortal. 
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Discussion 
In this study, I describe a novel mechanism of action for Beclin 1 in breast 
cancer involving its control of growth factor receptor signaling. Beclin 1 regulates 
PI3P lipid levels in response to growth factor stimulation to control the rate at 
which growth factor receptors transit through a signaling-competent early 
endosome compartment. In doing so, Beclin 1 controls the intensity and duration 
of growth factor stimulated AKT and ERK signaling. I demonstrate that 
suppression of BECN1 sustains growth factor stimulated AKT and ERK activation 
in breast carcinoma cells in vitro, and that an inverse correlation between Beclin 
1 expression and AKT and ERK phosphorylation is also observed in human 
breast tumors. Functionally, reduction of Beclin 1 expression enhances invasion 
in an AKT-dependent manner. Taken together, my data reveal a mechanism by 
which dysregulation of Beclin 1 expression or function contributes to malignant 
behavior. 
Beclin 1 is an independent prognostic factor for overall survival (OS) and 
distant metastasis-free survival in breast cancer, with low levels of Beclin 1 
expression predicting worse OS (97). Low Beclin 1 expression together with 
active WNT signaling also correlates with poor prognosis in breast cancer (146). 
However, the mechanism to explain how loss of Beclin 1 expression would 
contribute to aggressive tumor behavior remains unresolved. Autophagy, which 
is thought to support tumor progression by facilitating the survival of tumor cells 
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in stressful microenvironments that may lack sufficient oxygen and nutrients, is 
inhibited when Beclin 1 expression is decreased. My study provides evidence for 
an alternative mechanism of Beclin 1 action to explain how its loss promotes 
tumor progression. Specifically, we show that Beclin 1 loss enhances oncogenic 
signaling pathways such as AKT and MAPK that promote survival and invasion. 
In this direction, an autophagy-independent role for Beclin 1 loss has been 
suggested to contribute to the enhanced mammary stem and progenitor cell 
activity and tumorigenesis that is observed in Wnt1/Becn1+/- mice (146). Taken 
together with the recent Drosophila study showing that Beclin 1 regulates Notch 
trafficking, these findings support the possibility that multiple receptor trafficking 
pathways may be impacted by Beclin 1 loss and that this combined dysregulation 
culminates in enhanced signaling to promote tumor progression (170). 
I establish an important role for Beclin 1 in the regulation of early 
endosome maturation. Beclin 1 is required for the growth factor-stimulated 
generation of PI3P by PI3KC3, which facilitates the recruitment of FYVE domain 
containing proteins, such as EEA1, that promote endosome fusion and 
maturation (123, 171). Another FYVE-domain protein, Fab1/PIKfyve (FYVE-
containing phosphatidylinositol 3-phosphate 5-kinase), is recruited to 
Rab5+/PI3P+ endosomes where it is activated in response to phosphorylation by 
AKT(172). PIKfyve phosphorylates PI3P to generate PI-3,5-P and promote 
endosome progression to multivesicular bodies where signaling is terminated.  
Reduced PI3P production in the absence of Beclin 1 would be expected to limit 
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the recruitment of PIKfyve and therefore inhibit maturation. Finally, Beclin 1 
recruits UVRAG, which enhances PI3KC3 activation and PI3P production (16, 
113). UVRAG also promotes early endosome maturation by activating C-
VPS/HOPS to facilitate Rab7 recruitment and transition to the late endosome, a 
function that would also be lost in the absence of Beclin 1 (18).   
My studies model the reduction of Beclin 1 expression that occurs in many 
tumors (97, 98). Other tumors, however, may exhibit a decrease in Beclin 1 
function as a consequence of post-translational modifications, and this disruption 
would also be expected to impact growth factor receptor trafficking and signaling. 
For example, activated EGFR binds to Beclin 1 and promotes its phosphorylation 
on multiple tyrosine residues (32). These phosphorylation events disrupt the 
interaction of Beclin 1 with PI3KC3 and decrease its associated lipid kinase 
activity. Additionally, Beclin 1 is phosphorylated on S234 and S295 by AKT, 
which also disrupts PI3KC3 binding (31). These pathways likely function to 
regulate the rate of receptor trafficking and duration of signaling in normal cells, 
but when hyperactivated in tumors could further enhance their oncogenic 
signaling potential. In support of an involvement of this post-translational 
mechanism of regulation in cancer, expression of a Beclin 1 tyrosine 
phosphomimetic in NSCLC cells increased proliferation and stimulated enhanced 
tumor growth (32). Similarly, expression of a Beclin 1 mutant that is resistant to 
AKT phosphorylation inhibited Myr-AKT1-dependent tumorigenesis (31). 
Although these effects of the Beclin 1 phospho-mutants on tumor growth were 
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attributed to the impact of Beclin 1 on autophagy, dysregulated growth factor 
receptor signaling would also contribute to these phenotypes.  
My study differs from previous work that has focused exclusively on the 
effect of Beclin 1 loss on autophagy and the contribution of this degradative 
pathway to cancer. I reveal an alternative mechanism to account for how Beclin 1 
loss may impact tumor progression that involves enhancing the magnitude and 
duration of signals propagated through growth factor receptors, many of which 
have been identified as oncogenic drivers. Reduction of Beclin 1 expression in 
tumors would result in dysregulation of both growth factor receptor signaling and 
autophagy, and these pathways may work in concert to promote tumor 
progression. 
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Summary 
Autophagy is a complex process under the regulation of multiple signaling 
pathways that can either stimulate or repress the process. Dysregulation of some 
of these pathways is found to occur in a number of cancer types.  Moreover, the 
autophagic process itself has also been shown to both inhibit and promote 
tumorigenesis. My study was designed to investigate the role of autophagy and 
one of its important regulators, Beclin 1, in breast cancer progression. Work 
presented in this thesis as well as preliminary data implicate a dependency of 
triple-negative breast cancer (TNBC) cell lines on autophagy. These cells exhibit 
higher levels of basal and induced autophagy when compared with luminal 
breast carcinoma cells. Moreover, both chemical and genetic inhibition of 
autophagy decreased the tumorigenicity of a TNBC cell line as measured by 
anchorage-independent growth. These findings are consistent with a recently 
published study that reported an increased sensitivity of TNBC cell lines to 
autophagy inhibition when compared with luminal and non-tumorigenic cell lines 
(129). Taken together, my results and the above-mentioned study implicate that 
TNBC tumors may potentially benefit from autophagy-targeted chemotherapy. 
Interestingly, my study revealed different effects on glycolysis upon 
inhibition of two independent autophagic regulators – ATG5 and Beclin 1. 
Whereas suppression of ATG5 decreased glycolytic capacity, silencing Beclin 1 
did not affect aerobic glycolysis.  This result indicated a possible involvement of 
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alternative functions of Beclin 1 that counteract the loss of autophagy. The 
ATG5-independent, and hence presumably autophagy-independent, roles of 
Beclin 1 were further explored in the second part of my thesis. 
Non-autophagy functions of Beclin 1 have been described in lower 
organisms and are now being investigated in mammals. However, the tumor 
suppressive function of Beclin 1 has been ascribed mostly to its role in 
autophagy. In my study I focused on contributions of alternative functions of this 
protein and uncovered a novel role for Beclin 1 in regulating growth factor-
dependent signaling. Detailed analysis of the mechanism behind this regulation 
revealed a role for Beclin 1 in the maturation of early endosomes. As illustrated in 
Figure 5.1, I demonstrated that suppression of Beclin 1 expression inhibits PI3P 
production on early endosomes, which is necessary for maturation of these 
signaling-competent vesicles. As a result, termination of growth factor-dependent 
signaling is delayed. One of the consequences of the enhanced signaling that 
occurs upon Beclin 1 loss is increased breast carcinoma cell invasion. 
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Impact of Beclin 1 loss in cancer 
Several studies have shown that autophagy facilitates tumor progression 
by helping tumor cells survive in their stressful microenvironment (126). Inhibition 
of key regulators of this degradative pathway, other than Beclin 1, reduce 
proliferation, anchorage-independent growth and glycolysis (135). Moreover, 
autophagy has also been shown to promote invasion in Ras-driven tumors by 
production and secretion of pro-migratory factors such as interleukin-6 (IL-6) 
(173). Suppression of autophagy genes decreased the invasive capacity of tumor 
cells, which could be rescued by treatment with conditioned media from 
autophagy-competent cells. Knockdown of ATG genes also reduced cell 
migration in vitro and pulmonary metastasis in vivo (173). The tumor-promoting 
function of autophagy is further supported by the study performed by Takamura 
et. al. who reported that systemic mosaic deletion of Atg5 and liver-specific 
deletion of Atg7 in mice results in development of benign adenomas only in the 
liver. These adenomas do not progress to adenocarcinomas indicating a 
requirement of autophagy for tumor progression (108). This result is in contrast to 
heterozygous deletion of Becn1 in mice, which results in an increased rate of 
spontaneous malignancies (94).  Decreased expression of Beclin 1 in multiple 
human tumors further supports the tumor suppressive role of Beclin 1, unlike 
other autophagy regulators. The above-mentioned contradictory studies suggest 
the possible contribution of additional non-autophagy functions of Beclin 1 to 
cancer.  
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In support of an autophagy-independent role for Beclin 1 in tumor 
suppression it has been proposed that since the anti-apoptotic protein Bcl-2 
binds to Beclin 1, loss of the latter can promote cell survival and hence 
tumorigenesis. Interestingly, Beclin 1 as part of the PI3KC3 complex can also 
control the levels of the tumor suppressor p53 by regulating the stability and 
activity of the p53 deubiquitinating enzymes, USP10 and USP13. As a result, 
reduction in Beclin 1 expression results in reduced levels of p53. These findings 
indicate a potential mechanism that can promote the genomic instability that is 
observed upon loss of Beclin 1 (174). Since Beclin 1 has also been reported to 
be involved in regulating cytokinesis, loss of this protein may also directly result 
in genomic instability causing aneuploidy (19). My studies demonstrate an 
additional function of Beclin 1 that could contribute to tumor suppression, thus 
underscoring the importance of the long neglected autophagy-independent role 
of the protein. By regulating signals propagated through growth factor receptors, 
many of which have been identified as oncogenic drivers, Beclin 1 can exert its 
tumor suppressive function. 
My data reveal that one of the functional outcomes of enhanced signaling 
in Beclin 1-deficient cells is an increase in invasive potential, a characteristic 
required for tumor cells to metastasize. In addition, Beclin 1-depleted cells are 
also able to maintain high glycolytic rates, unlike ATG5-depleted cells. Since 
activated AKT and MAPK are involved in cell growth, proliferation, survival and 
metabolism, hyper-activation of growth factor receptor-mediated signaling in 
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Beclin 1-depleted cells could be responsible for restoring glycolytic rates in these 
tumor cells. One of the mechanisms by which PI3K/AKT signaling controls 
glycolysis is by regulating localization of GLUT1 to the cell surface (122, 145). 
Enhanced PI3K/AKT signaling increases glycolysis that results in generation of 
lactic acid, a byproduct of glycolysis. Lactic acid can, in turn, facilitate tumor cell 
invasion by promoting the degradation of the extracellular matrix. Furthermore, 
suppression of Glut1 expression in mouse mammary tumor cells has been 
reported to inhibit both glucose uptake and tumor cell invasion (122). These facts 
indicate that the elevated PI3K/AKT signaling in Beclin 1-depleted cells could 
result in increased GLUT1 expression on the cell surface, thereby promoting 
aerobic glycolysis and cancer cell invasion. This hypothesis can be further 
investigated by comparing aerobic glycolysis and invasion of shATG5 and 
shBECN1 cells upon treatment with AKT inhibitors as well as by silencing GLUT1 
expression. My observations also implicate that the requirement of autophagy for 
maintaining the metabolic fitness of tumor cells could be counter-balanced by 
enhanced signaling in Beclin 1-depleted cells.  
Beclin 1 deletion in cancer is monoallelic, indicating the possibility that low 
levels of autophagy still occur. My studies show that suppression of Beclin 1 
enhances receptor-mediated signaling. Based on these facts it is possible that 
decreased Beclin 1 expression in tumors promotes progression and metastasis 
due to enhanced oncogenic signaling while maintaining low levels of autophagy 
to sustain cancer cells in the nutrient-depleted tumor microenvironment. To 
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further understand the interplay between the two functions of Beclin 1 - 
autophagy and modulation of receptor-mediated signaling in tumorigenesis - in 
vivo investigation is warranted. The effect of decreased expression rather than 
complete loss of Beclin 1 on tumor formation and metastasis should be studied. 
Mice with conditional, inducible, monoallelic deletion of Becn1 in the mammary 
gland could be used for this analysis. These mice would allow for the 
investigation of tumor formation and progression upon heterozygous loss of 
Becn1 in a specific tissue at a specific age, unlike previous studies that were 
performed with Becn1+/- mice. Activation of AKT and MAPK as well as the 
presence of autophagosomes can be analyzed in the tumors to monitor 
autophagy and signaling. Furthermore, the contribution of the tumor 
microenvironment in supporting the growth and metastatic ability of Beclin 1-
depleted cells should be assessed. Cancer-associated fibroblasts (CAFs) can 
undergo autophagy induced by the stressful tumor microenvironment resulting in 
the secretion of metabolites that can be taken up by Beclin 1-depleted cancer 
cells (175-177). Thus, the tumor microenvironment may counter-balance the 
inhibitory effects of decreased availability of intermediates for metabolic 
pathways and macromolecular biosynthesis by metabolically coupling with 
Beclin1-deficient cells.  
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Beclin 1 in human tumors 
The tumor suppressive function of Beclin 1 has recently been challenged 
by a study that investigated the mutational status of BECN1 in human tumor 
sequencing data obtained from The Cancer Genome Atlas (TCGA). This study 
found that BECN1 was deleted only in conjunction with its proximal breast and 
ovarian tumor suppressor gene BRCA1 in breast and ovarian cancers. Moreover, 
BECN1 was not found to be mutated or focally deleted in other cancers (95). 
However, aberrant protein expression has been reported in several human 
tumors (96-98). Analysis of 378 ER+, HER2- breast cancer patients revealed that 
patients with low Beclin 1 expression displayed decreased overall survival and 
distant metastasis-free survival implicating Beclin 1 as a negative prognostic 
factor (97). Moreover, comparison of 20 pairs of sporadic breast tumors with 
adjacent normal tissues revealed aberrant methylation of the promoter and intron 
2 of BECN1 in tumors expressing low levels of the protein. These data suggest 
that Beclin 1 expression can also be reduced by epigenetic regulation of the 
gene (96). Furthermore, overexpression of Beclin 1 in MCF7 cells reduces 
proliferation in vitro and tumorigenesis in nude mice (4). Above all, it is well 
established that heterozygous loss of Becn1 in mice leads to spontaneous tumor 
formation (35, 94). Based on these facts, I would argue that Beclin 1 should still 
be considered a haploinsufficient tumor suppressor. 
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I demonstrated that loss of Beclin 1 can enhance growth factor-receptor 
signaling and promote invasion. Elevated AKT and MAPK signaling can activate 
the autophagy inhibitor mTORC1, thereby inhibiting autophagy. However, cancer 
cells require autophagy, especially in the poorly perfused interior sections of the 
tumor. Thus, it is possible that tumor cells could epigenetically silence BECN1 to 
promote invasion and metastasis. Once at the secondary site, Beclin 1 
expression could be restored, owing to the plasticity of epigenetic alterations, to 
promote growth of the metastatic lesion. In support of this hypothesis, my 
analysis of hypermethylation of BECN1 in the basal MDA-MB-231, luminal MCF7 
and immortalized normal mammary epithelial cell line MCF10A revealed that 
BECN1 is epigenetically suppressed in the metastatic MDA-MB-231 cells but not 
in the non-metastatic MCF7 and MCF10A cells (Appendix Figure 1). Further in 
vivo studies are required to determine if suppression of Beclin 1 is essential to 
support invasion and metastasis of this autophagy-dependent cell line. 
Analysis of human breast tumor data from cBioPortal for Cancer 
Genomics revealed a negative correlation between Beclin 1 expression and AKT 
and ERK phosphorylation in a cohort of breast cancer patients that had altered 
levels of Beclin 1 protein expression. My studies demonstrate that Beclin is 
involved in spatio-temporal regulation of receptor-mediated signaling. Through in 
vitro studies I have shown that suppression of Beclin 1 leads to increased AKT 
and MAPK activation. My findings provide a potential explanation for the negative 
correlation between Beclin 1 expression and AKT and ERK activation in breast 
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cancer. To confirm this, activation of AKT and MAPK pathways should be 
evaluated in tumors formed in mice upon depletion of Beclin 1 protein levels. 
Moreover to confirm the cause (low Beclin 1 expression) and effect (increased 
signaling) relationship, protein expression of Beclin 1 could be monitored upon 
treatment with AKT and/or MAPK inhibitors. Based on my results, loss of Beclin 1 
enhances AKT and MAPK signaling. Hence, the potential use of inhibitors of 
these pathways to treat Beclin 1-deficient tumors should also be explored. 
Regulation of Beclin 1 function by signaling pathway components 
Signaling pathways that are frequently overexpressed/hyperactivated 
have been reported to regulate the function of Beclin 1 in autophagy. Multisite 
tyrosine phosphorylation of Beclin 1 by activated EGFR reduces PI3KC3 activity 
and autophagy. Interaction of activated EGFR with Beclin 1 increases its binding 
with the negative regulators Bcl-2 and Rubicon, and decreases PI3KC3 
association with Beclin 1. Moreover, Beclin 1 tyrosine phosphomimetic mutant 
expression enhanced tumor growth and dedifferentiation of non-small-cell lung 
carcinoma xenografts (32). Similarly AKT-mediated phosphorylation of Beclin 1 
inhibits autophagy. Additionally, expression of a non-phosphorylatable mutant of 
Beclin 1 suppressed AKT-mediated tumorigenesis and anchorage-independent 
growth and increased autophagy (31). In both of these reports, increased 
tumorigenesis was attributed to inhibition of autophagy. However, my findings 
also indicate a possible role for enhanced endosomal signaling in increased 
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tumorigenesis. Phosphorylation of Beclin 1 by aberrant activation of EGFR and 
AKT would lead to decreased PI3KC3 activity and hence delayed endosomal 
maturation. This would further enhance oncogenic signaling from signalosomes 
(signaling endosomes).  Taken together, these data indicate that not only 
reduced expression of Beclin 1, but also its post-translational modification 
leading to decreased Beclin 1 function, could promote tumor development and 
progression. This hypothesis can be tested by analyzing the number of 
Rab5+/PI3P- early endosomes (using markers such as APPL1) in human tumors 
with activated EGFR/AKT and phosphorylated Beclin 1 and comparing these 
tumors with Beclin 1 deficient tumors and normal tissue. In vitro expression of 
Beclin 1 phosphomimetics and their effect on signaling should also be explored. 
Based on my data, expression of Beclin 1 phosphomimetics would also enhance 
growth factor receptor signaling, similar to that seen upon suppression of Beclin 
1 expression. 
Role of Beclin 1 complexes in oncogenic signaling 
The work presented in this dissertation provides new insight into the 
molecular mechanism by which Beclin 1 could function as a tumor suppressor. 
These findings give rise to additional questions. Future studies investigating the 
role of ATG14L and UVRAG on growth factor-dependent signaling should be 
performed to define the contribution of both complex I and II in tumorigenesis and 
metastasis. UVRAG, a component of complex II, enhances PI3KC3 activation 
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and PI3P production (16, 113). It also promotes early endosome maturation by 
activating C-VPS/HOPS to facilitate Rab7 recruitment and transition to the late 
endosome, a function that would also be lost in the absence of Beclin 1 (18). A 
role for UVRAG in controlling EGFR degradation has been previously reported. 
siRNA mediated depletion of UVRAG decreased EGFR receptor degradation 
(19). In addition, UVRAG is frequently monoallelically mutated in human colon 
carcinomas with microsatellite instability (113). All of these reports, together with 
my finding that ATG5 does not control receptor signaling, supports an 
autophagy-independent mechanism of regulation by Beclin 1 (complex II).  
One of the caveats of inhibiting Beclin 1 is that it could affect both 
autophagy and endocytic vesicle trafficking. Hence, it is concievable that 
inhibition of the autophagic pathway in Beclin 1-depleted cells may also 
contribute to increased oncogenic signaling. Although we did not observe any 
increase in the activation of AKT upon chemically inhibiting autophagy with 
chloroquine or genetically suppressing ATG5, inhibition of this process could 
delay degradation of growth factor receptor pathway components. In support of 
this possibility, the number of APPL+ endosomes increased modestly at the very 
earliest time point of stimulation in ATG5-deficient cells. This increase in 
signaling-competent early endosomes could result in a transient increase in 
growth factor-dependent signaling. To investigate this impact on signaling, a 
shorter-duration growth factor stimulation should be performed with ATG5-
depleted cells and its effect on invasion and tumor progression should be 
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monitored. It is also plausible that the observed differences in growth factor 
receptor signaling in shBECN1 and shATG5 cells are due to inefficient 
suppression of autophagy in the latter. Therefore, the extent of autophagy 
inhibition in shBECN1 and shATG5 cells should be compared by quantitative 
analysis of this degradative process by methods such as transmission electron 
microscopy.  
To further delineate the contribution of autophagy and vesicle trafficking in 
regulating growth factor receptor-mediated signaling, Beclin 1-depleted cells 
rescued with wild type Beclin 1 should be compared with shBECN1 cells rescued 
with Beclin 1 mutants that bind only UVRAG or ATG14L. Based on my findings 
and previous reports, complex II is involved in endocytic vesicle trafficking, a 
process known to regulate receptor-mediated signaling. Hence rescue of Beclin 
1-deficient cells with the UVRAG-binding mutant would be predicted to restore 
signaling to control levels, whereas the ATG14L-binding mutant would not.  
The impact of Beclin 1 on endosomal maturation 
The role of Beclin 1 in endocytosis in lower organisms including C. 
elegans and Drosophila has been well documented (82, 83, 170). However, its 
function in mammals had been controversial. My data confirms the involvement 
of Beclin 1 in receptor endocytosis and contributes to a better understanding of 
the molecular mechanism by which receptor tyrosine kinases traffic, defects in 
which promote tumorigenesis (178). The requirement of Beclin 1 for maturation 
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of PI3P- endosomes to PI3P+ endosomes have been supported by a very 
recently published study by McKnight et. al. (179) where they report the need for 
the Beclin 1-PI3KC3 complex II (containing UVRAG) but not complex I 
(containing ATG14L) for endosome maturation and EGFR down-regulation. They 
demonstrated that Beclin 1 associates with endosomes in neurons under normal 
conditions. Similar to my results, they too found that Beclin 1 deficiency reduced 
PI3KC3 activity and generation of PI3P, resulting in decreased PI3P+ endosome 
formation. Additionally, they also demonstrated that impaired PI3P+ endosome 
formation in Beclin 1-deficient cells could be rescued by over expression of 
UVRAG but not ATG14L, RUBICON or a UVRAG-binding deficient Beclin 1 
mutant, implicating the involvement of complex II in endocytosis. These results 
support my findings that Beclin 1 controls endosomal maturation. Furthermore, 
my studies have also demonstrated that Beclin 1 modulates growth factor 
receptor signaling from early PI3P- endosomes, resulting in increased invasive 
capabilities of Beclin 1-depleted cells and potentially increased glycolytic rates, 
both of which promote tumor progression. Hence, my results advance our 
understanding of Beclin 1 in cancer and perhaps other pathogenic conditions. 
The phospholipid PI3P is involved in several important cellular functions 
including signaling, membrane trafficking and phagocytosis (180). Since Beclin 1 
promotes PI3P production, decreased expression of this protein can affect all the 
above-mentioned processes. Moreover, receptor endocytosis is being used for 
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targeted drug delivery to the endolysosomal system (181). Since Beclin 1 
regulates endosomal trafficking, decreased Beclin 1 expression may lead to 
reduced efficacy of such drugs.  
Targeting autophagy for cancer treatment 
The tumor suppressing and tumor promoting function of autophagy has 
been highlighted by a number of studies. Because of its involvement in tumor 
growth and progression, autophagy has been considered as a target for cancer 
therapy, which in turn has led to several clinical trials. However, autophagy can 
be cytoprotective and help cells survive therapy making them resistant or could 
also be cytotoxic as excessive autophagy can lead to cell death. Due to its 
paradoxical role in cancer, understanding the function of autophagy in a given 
cancer type is crucial before modulators of the process can be used for cancer 
treatment. My studies indicate that triple-negative breast carcinoma cells could 
be good candidates for autophagy-targeted therapy. Nonetheless targeting 
PI3KC3 or Beclin 1 to inhibit autophagy for cancer treatment may prove 
deleterious. Contradictory results were obtained by Kanzawa et. al. upon 
treatment of malignant glioma cells with 3-methyladenine, a PI3KC3 inhibitor, 
and Bafilomycin A1 which inhibits fusion between autophagosomes and 
lysosomes. Bafilomycin A1 sensitized glioma cells to chemotherapeutic drugs 
while 3-methyladenine rescued them (182). The results presented in this thesis 
could potentially explain these conflicting results. Inhibition of PI3KC3 could 
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enhance oncogenic survival signals thereby counteracting therapy-induced 
apoptosis.  
Recently, PI3KC3 has also been gaining importance as an anticancer 
agent. PI3KC3 specific inhibitors are being developed to inhibit autophagy in 
cancer cells (183, 184). Though this treatment may be beneficial when used in 
combination with inhibitors of pathways such as AKT and MAPK, it could also 
lead to upregulation of other signaling pathways. The results of my study indicate 
that patients with autophagy-dependent triple-negative breast tumors could be 
good candidates for treatment with autophagy inhibitors. However, inhibition of 
PI3KC3 complex activity should be avoided to prevent progression of the disease. 
Since Beclin 1 is a regulator of endosomal signaling, its affect may be more 
global and encompass multiple signaling pathways. Thus, to target all the 
pathways, the possibility of rescuing Beclin 1-deficient cells by addition of 
exogenous PI3P may be explored in the future. 
Overall significance 
In the present study I have explored autophagy-dependent and 
independent functions of Beclin 1 in tumor progression. I (and others) have found 
that triple-negative breast carcinoma cells are potentially autophagy dependent 
and hence these tumors could be good candidates for treatment with autophagy 
inhibitors. I also identified a novel role for the essential autophagy gene Beclin 1 
in modulating growth factor receptor trafficking and signaling. Beclin 1, by 
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regulating the residence time of growth factor receptors in early signaling-
competent endosomes, controls the magnitude and duration of signals 
propagated. My studies reveal that loss of Beclin 1 could negatively affect two 
degradative pathways – autophagy and endocytosis, both of which could 
contribute to tumor progression.  
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APPENDIX 
 
 
ANALYSIS OF EPIGENETIC REGULATION OF BECN1 IN 
BREAST CARCINOMA CELLS 
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Beclin 1 expression is frequently downregulated in breast tumors both by 
allelic loss as well as aberrant DNA methylation. This protein maps to human 
chromosome 17q21 which is monoallelically deleted in 40% - 75% of ovarian, 
breast and prostate cancers (93). The 5’ regulatory region from the promoter to 
part of intron 2 of BECN1 is rich in CpG islands and is also epigenetically 
silenced in many breast tumors (96). A study performed by Aita et. al. reported 
allelic deletion of BECN1 in 41% of breast carcinoma cell lines analyzed when 
compared to the normal immortalized mammary epithelial MCF10A cells. Their 
results indicate deletion of BECN1 in MCF7 but not MDA-MB-231 cells (93). I 
sought to investigate whether BECN1 was also epigenetically regulated in these 
cell lines belonging to different breast cancer subtypes.  
To analyze hypermethylation of BECN1 in the triple-negative MDA-MB-
231, luminal MCF7 and immortalized normal mammary epithelial MCF10A cell 
lines, cells plated in triplicate were treated with 6µM and 8µM of 5-aza-2’-
deoxycytidine for 72 hours. Control plates were treated with an equal volume of 
DMSO. Media was replaced each day with fresh media containing either DMSO 
or 5-aza-2’-deoxycytidine. After 72 hours, cells were harvested and RNA was 
extracted using the RNeasy kit (Qiagen). Superscript® II Reverse Transcriptase 
(Invitrogen) was used to synthesize cDNA, which was subsequently utilized to 
quantify BECN1 gene expression using SYBR® Green RT-PCR reagents 
(Applied Biosystems). BECN1 expression was normalized to actin. 
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Inhibition of DNA methylation revealed that BECN1 expression was 
enhanced by 1.8 – 2 fold upon treatment of MDA-MB-231 cells with 5-aza-2’-
deoxycytidine. However, no significant difference in BECN1 expression was 
detected in MCF7 and MCF10A cells treated with the inhibitor. These results 
indicate that Beclin 1 is epigenetically suppressed in the metastatic MDA-MB-231 
cells, but not in the non-metastatic MCF7 and MCF10A cells.  Although Beclin 1 
is a key player in the autophagic process, I have also demonstrated that loss of 
this protein can promote invasion. Hence, it is possible that cancer cells 
epigenetically regulate BECN1 expression during tumor progression to promote 
invasion and metastasis. Further in vivo studies are required to test this 
hypothesis. 
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Appendix Figure 1. Epigenetic regulation of Beclin 1. 
MDA-MB-231 (A), MCF10A (B) and MCF7 (C) cells were treated with 5-aza-2’-
deoxycytidine (Decitabine) at the concentrations indicated for 72 hours. RNA was 
extracted, reverse transcribed and BECN1 mRNA levels were determined by qRT-PCR. 
The data shown represent the mean of four (MDA-MB-231; n=12) or three (MCF10A and 
MCF7; n=9) independent experiments. *, p < 0.05 ; ***,  p < 0.0005; n.s, not significant. 
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